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CHAPTER 1:  
INTRODUCTION
While Massachusetts has a long history as a leading state for 
health care access and innovation, the affordability of the state’s 
overall high-quality health care continues to be a challenge. 
In an effort to restrain rapidly increasing health care costs, 
comprehensive health care reform legislation passed in 2012 
set a first-in-the-nation statewide target for sustainable growth 
in total health care spending (3.6 percent) and established 
the independent Massachusetts Health Policy Commission 
(HPC) to help monitor and guide this ambitious effort (see 
Sidebar: What is the Role of the Massachusetts Health Policy 
Commission?). Seven years later, the HPC has reported mean-
ingful progress towards health care cost containment in the 
Commonwealth. Overall, since the benchmark was established, 
the state’s health care spending has grown at a below-the-
benchmark average annual rate of 3.4 percent. Most recently, 
from 2017 to 2018, the state’s preliminary health care spending 
growth was 3.1 percent, equaling the newly lowered benchmark 
target for 2018 (Exhibit 1.1). Massachusetts total health care 
spending growth (including both public and private payers) 
has been below national growth rates for the ninth consecutive 
year, a reversal from previous trends.
In this annual report, the HPC presents new research to further 
enhance the collective understanding of health care spending 
trends and cost drivers in the Commonwealth, and evaluates 
the state’s progress in meeting several cost containment, care 
delivery, and payment system goals set by the Commonwealth 
and the HPC. The report examines the market dynamics and 
spending drivers in two areas of particular interest: hospital 
inpatient and hospital outpatient services. These were two 
of the fastest growing health care spending categories from 
2017 to 2018 (3.7 percent and 3.8 percent, respectively) and 
together account for over 40 percent of all health care spend-
ing in Massachusetts. Based on this analysis and other HPC 
research and programs, the report also includes a set of rec-
ommendations for policymakers as well as providers, payers, 
employers, patients, and other health care market participants 
who work collaboratively toward a more high-value system.
By many important indicators, Massachusetts has a high per-
forming health care system. As the forerunner to the federal 
Patient Protection and Affordable Care Act (ACA), the state 
has the lowest rate of uninsured residents in the U.S. Again this 
year, Massachusetts ranked first in the Commonwealth Fund’s 
2017-20182016-20172015-20162014-20152013-20142012-2013
2.4%
4.2%
4.8%
3.0%
2.8%
3.1%
BENCHMARK: 3.1%
2012 – 2017
BENCHMARK: 3.6%
Notes: 2017-2018 spending growth is preliminary.
Sources: Center for Health Information and Analysis Annual Report, 2019
Exhibit 1�1 Annual growth in total health care expenditures per capita in Massachusetts
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scorecard on state health system performance in the categories 
of access and prevention and treatment.1 The United Health 
Foundation, a nationally recognized organization dedicated 
to improving health and health care, ranked Massachusetts 
as the second healthiest state in the country.2 Massachusetts 
is home to many renowned health care institutions that pos-
itively contribute to health care research and education for 
the entire world. The state’s thriving life sciences industry 
generates foundational scientific advances leading to drugs 
and treatments that improve and save lives.
However, there are a number of metrics of health system per-
formance in which Massachusetts trails the country. Despite 
ranking as a very healthy state, emergency department, hospital 
outpatient, and acute care hospital use in Massachusetts are 
above national averages, and the hospital readmissions rate 
in Massachusetts is higher than nearly every state in the U.S. 
The higher utilization of care in intensive and costly settings in 
Massachusetts may reflect a number of factors such as patient 
preference or richer benefits and may, in some cases, reflect 
greater access to necessary care. However, these data also reflect 
some care that may have been unnecessary, is excessively priced, 
or which could have been safely delivered in lower cost settings. 
The Commonwealth Fund’s scorecard ranked Massachusetts 
31st in the nation for avoidable hospital use and costs, while 
the United Health Foundation ranked Massachusetts 37th in 
preventable hospitalizations.1, 2 Massachusetts’ place in the 
variation between states warrants attention, given the impli-
cations of avoidable use of intensive care settings for patient 
experience and overall health system spending.
Massachusetts also faces continued health equity challenges. 
As detailed in the Department of Public Health’s 2017 Mas-
sachusetts State Health Assessment, persistent disparities in 
health outcomes remain among low-income communities, 
people of color, LGBTQ+ individuals, and other populations, 
despite Massachusetts’ long-standing commitments to inclusive 
health care reform and access to care.3 Additionally, while 
the Commonwealth Fund’s scorecard still ranks Massachu-
setts highly on the category of “disparities based on income,” 
Massachusetts dropped five places in this category (to 7th in 
the nation) in the most recent year.
Health care affordability is also a significant and growing 
challenge. Premium growth has far outpaced general price 
inflation, with employees paying an increasing share. Between 
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Notes: Total family premium includes the portion of the premium paid by employees and the part paid by the employer. Personal 
income refers to income per capita in Massachusetts. General inflation refers to changes in the Consumer Price Index (CPI-U).
Sources: HPC analysis of Medical Expenditure Panel Survey (MEPS), Bureau of Labor Statistics (BLS), and Federal Reserve data, 
2000-2018
Exhibit 1�2 Growth of premiums, income, and inflation in Massachusetts, 2000 – 2018
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2000 and 2018 in Massachusetts, the consumer price index 
grew by 50 percent, while the average cost for a family pre-
mium nearly tripled, from $7,341 to $21,801 (Exhibit 1.2). 
Employees’ direct premium contributions rose even faster 
(by a factor of nearly four) as employees paid an increasingly 
larger share of premiums over this time period out of their 
paychecks (increasing from 21 percent of the premium being 
paid by employees to 26 percent).4 In addition to paying higher 
premiums, individuals and families are also paying substan-
tially more in cost-sharing and other out-of-pocket spending. 
Cost-sharing has risen even faster than premium growth in the 
past several years, and nearly one-third of privately insured 
Massachusetts residents now have high-deductible health plans.5
The growth in health care costs contributes to financial chal-
lenges for many families. In 2017, one in four Massachusetts 
residents reported having gone without needed medical or 
dental care due to cost, and 17 percent reported having family 
medical debt.6 In 2019, one in four Massachusetts residents 
reported forgoing medically necessary prescription drugs, 
resulting in difficult choices (rationing or cutting pills) and 
ultimately worsening health for many residents.7 As detailed in 
this report, high health care costs in Massachusetts dispropor-
tionately burden low- and middle-income families, non-white 
families, and families with greater health care needs, among 
other populations. Affordability challenges in Massachusetts 
echo national trends, with the share of Americans postponing 
medical care for a serious condition due to costs doubling in 
the last 20 years, from 12 percent in 2001 to 25 percent in 
2019 – the highest level ever recorded.8
This report is being released in the context of robust discus-
sions about the future of health care nationally, as well as in 
Massachusetts and in states across the U.S. In late 2019, the 
Baker-Polito Administration proposed comprehensive health 
care reform legislation that builds on past reforms, provides 
new tools for health care market accountability, and sets 
bold new goals for improving primary and behavioral health 
care, among many notable provisions. Leaders in the Massa-
chusetts House of Representatives and Senate have similarly 
committed to advancing the next phase of health care cost con-
tainment legislation this year. The recommendations included 
in this report are intended to inform this debate and identify 
high-priority areas for policy action based on data, evidence, 
and lessons learned.
Therefore, despite considerable and persistent cost and equity 
challenges, Massachusetts is uniquely positioned to continue 
to lead the nation in advancing a high performing, high value, 
and affordable health care system. Inspired by the success of 
Massachusetts, a number of states around the country have 
recently established health care cost containment goals and 
monitoring government agencies. In early 2020, the Altarum 
Healthcare Value Hub ranked states on their efforts to improve 
health care affordability, citing Massachusetts as first in the 
nation for its efforts to date.9
Nonetheless, as evidenced by the findings contained in this 
report and other HPC research, it is clear that further policy 
action and a redoubled commitment from health care market 
participants is needed to realize this promise for the next 
decade. The HPC stands ready to support these efforts with 
data insights and independent policy leadership.
HOW THE REPORT IS ORGANIZED
The report includes material in two formats, a narrative written 
report and a graphical chartpack. This report is informed by 
the research of the Center for Health Information and Analysis 
(CHIA) and the Massachusetts Attorney General’s Office (AGO), 
as well as by presentations and testimony submitted during the 
HPC’s 2019 Annual Health Care Cost Trends Hearing.
Chapter 2 of the report compares health care cost growth in 
2018 to the state’s health care cost growth benchmark and 
discusses trends and levels of health care spending in Massa-
chusetts and the nation overall. Chapter 3 analyzes drivers of 
hospital inpatient spending in two sections, presenting evidence 
on how hospital coding intensity efforts contribute to rising 
inpatient spending despite a constant or declining number of 
hospital stays, and exploring shifts in care from inpatient to 
outpatient settings. Chapter 4 examines the factors that result 
in hospital outpatient care being the highest growth sector of 
health care in Massachusetts. The HPC’s policy recommen-
dations for improving efficiency in health care spending and 
quality of care in Massachusetts can be found in Chapter 5 at 
the end of the report, along with a dashboard summarizing 
performance on key measures.
The chartpack presents updated results and trends previously 
reported on by the HPC. These include areas for improvement 
in care delivery performance, such as decreasing avoidable 
hospital inpatient and emergency department utilization and 
maximizing value in post-acute care, and progress in aligning 
incentives, including expanding the use of alternative payment 
methods. The chartpack also explores variation in practice 
patterns and spending by provider organization, including 
use of low value care services.
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SIDEBAR: WHAT IS THE ROLE OF THE 
MASSACHUSETTS HEALTH POLICY 
COMMISSION?
The Massachusetts Health Policy Commission (HPC), 
established in 2012, is an independent state agency 
charged with monitoring health care spending growth in 
Massachusetts and providing data-driven policy recom-
mendations regarding health care delivery and payment 
system reform. The HPC’s mission is to advance a more 
transparent, accountable, and innovative health care 
system through independent policy leadership and inno-
vative investment programs. The HPC’s goal is better health 
and better care – at a lower cost – for all people across the 
Commonwealth.
HPC staff and its Board of Commissioners work collab-
oratively to monitor and improve the performance of the 
health care system. Key activities include setting the 
health care cost growth benchmark; setting and mon-
itoring provider and payer performance relative to the 
health care cost growth benchmark; creating standards 
for care delivery systems that are accountable to better 
meet patients’ medical, behavioral, and social needs; ana-
lyzing the impact of health care market transactions on 
cost, quality, and access; investing in community health 
care delivery and innovations; and safeguarding the rights 
of health insurance consumers and patients regarding 
coverage and care decisions by health plans and certain 
provider organizations.
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CHAPTER 2:  
TRENDS IN SPENDING 
AND CARE DELIVERY
Health care spending growth in Massachusetts in 2018 exactly 
matched the benchmark rate (3.1 percent) and was below the 
national trend for the 9th consecutive year. 
3.1%
Employee premium contributions for family coverage for 
workers in low-wage firms have risen rapidly in recent 
years and now exceed $8,000 per year ($683 per month) on 
average, higher than for other workers (less than $6,000 per 
year, or $500 monthly).
$
Health care spending growth in Massachusetts between 2016 
and 2018 absorbed almost 40 cents of every additional dollar 
earned for families with coverage through employers, more 
than they took home in pay after taxes. 
40¢
Spending growth per enrollee varied by sector with both 
commercial (4.6 percent) and Medicare FFS (3.9 percent) 
exceeding the benchmark, and MassHealth below  
(2.6 percent).
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CHAPTER 2:  
TRENDS IN SPENDING AND CARE DELIVERY
The Commonwealth’s landmark health care cost containment 
law, Chapter 224 of the Acts of 2012,1 establishes a benchmark 
for sustainable growth in health care spending, recognizing that 
containing spending growth is critical to easing the burden of 
health care spending on government, households, and busi-
nesses. Chapter 224 directs the Massachusetts Health Policy 
Commission (HPC) and the Center for Health Information 
and Analysis (CHIA) to monitor health care spending growth 
annually relative to the benchmark, which is indexed to a pro-
jection of the Commonwealth’s long-term economic growth.
From 2013 to 2017, the benchmark for annual health care 
spending growth was set at 3.6 percent. From 2018 to 2022, 
the benchmark was set by law to equal potential gross state 
product minus 0.5 percent, or 3.1 percent, but the HPC has 
limited authority to increase it back up to 3.6 percent. On 
March 29, 2017, the HPC board voted unanimously to main-
tain the benchmark at 3.1 percent for the 2018 calendar year 
relative to 2017 – the period of focus for much of the data 
presented in this chapter. This chapter also discusses broader 
trends regarding health care spending, value, and performance 
in the Commonwealth (see Sidebar: Factors Underlying Health 
Care Spending).
SIDEBAR: FACTORS UNDERLYING 
HEALTH CARE SPENDING
Total health care spending is a function of the prices of 
health care services as well as health care utilization. Utiliza-
tion, in turn, is affected by both the number of people who 
use health care services and the frequency and intensity 
of the services they receive. The HPC’s Annual Health Care 
Cost Trends Report examines the latest changes in both 
prices and utilization in Massachusetts, as well as factors 
that may explain and contextualize these recent trends 
in health care spending. This report largely focuses on 
aspects of the health care system that can be influenced 
by policymakers, government agencies, and market partici-
pants in the state, instead of population health factors such 
as aging of the population and other underlying changes 
in health status.
SPENDING GROWTH FROM 2017-2018
The measure of spending growth that is compared to the 
benchmark is the change in Total Health Care Expenditures 
(THCE) per state resident. THCE includes health care spending 
incurred by individuals, the state, and the federal government 
via Medicaid (MassHealth) and Medicare, as well as commer-
cial spending as reported by health insurers to CHIA. CHIA 
reported that, from 2017 to 2018, the per capita growth in 
THCE in Massachusetts was 3.1 percent, matching the bench-
mark set by the HPC.2 Total spending increased from $58.8 
billion in 2017i to $60.9 billion in 2018,ii while the state’s 
population grew by 0.6 percent over the same time period, 
resulting in an increase in per capita spending from $8,562 
to $8,827. This marks the first year that THCE growth was 
measured against the lower 3.1 percent benchmark, after two 
years of trending below the previous benchmark of 3.6 percent. 
From 2012 to 2018, six years since the passage of Chapter 224 
for which THCE growth has been assessed, the average annual 
spending growth rate has been 3.38 percent.
Exhibit 2�1 Annual growth in total health care expenditures per 
capita in Massachusetts
Notes: 2017-2018 spending growth is preliminary.
Sources: Center for Health Information and Analysis Annual Report, 2019
i Final assessment of 2016-2017 THCE per capita growth was revised 
upward from 1.6% to 2.8%. This difference in preliminary and 
final THCE per capita growth was driven primarily by two payers 
identifying and removing payments made by third parties that were 
reflected elsewhere in THCE.
ii This figure is preliminary.
2017-20182016-20172015-20162014-20152013-20142012-2013
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4.8%
3.0%
2.8%
3.1%
BENCHMARK: 3.1%
2012 – 2017
BENCHMARK: 3.6%
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While the state met the 3.1 percent spending growth 
benchmark in the aggregate in 2018, there were 
differences in performance by market segment (see 
Exhibit 2.2). In the commercial sector, spending 
grew 3.9 percent in total while enrollment declined 
slightly, resulting in spending growth per enrollee of 
4.6 percent– substantially above the benchmark.iii For 
MassHealth enrollees who receive full coverage under 
either the Primary Care Clinician (PCC) program or 
through a managed care organization (MCO), most of 
whom transitioned by 2018 into one of MassHealth’s 
new Accountable Care Organization (ACO) programs, 
spending per enrollee grew 2.6 percent, the lowest of 
any major market sector; total enrollment declined 
by 1.8 percent.iv In the Medicare program, spending 
per enrollee also grew faster than the benchmark 
(3.9 percent) for the roughly three-fourths of Massa-
chusetts Medicare beneficiaries enrolled in traditional 
(fee-for-service or FFS) Medicare, while spending 
growth per enrollee was just below the benchmark 
(3.0 percent) for enrollees in privately-administered 
Medicare Advantage, which also saw a 5.4 percent 
surge in enrollment.
The increase in Medicare spending per enrollee con-
trasts with prior years in which spending growth per 
enrollee has been below the benchmark and even nega-
tive in some years (a reduction in spending). Medicare 
spending in the FFS program was also relatively high in 
the U.S. overall in 2018 (see Exhibit 2.3), but growth 
in Massachusetts was higher in every category of care 
except for skilled nursing facilities. Per enrollee Medi-
care spending for hospital inpatient services increased 
by 2.9 percent in Massachusetts last year, nearly triple 
the national rate. Home health Medicare spending 
per enrollee in Massachusetts grew by 2.1 percent, 
also far above the national rate; this could reflect a 
shift from skilled nursing facilities where spending 
declined 3.1 percent in Massachusetts, also in excess 
of the national rate (see Chartpack that explores the 
decline in institutional post-acute care use).
iii This growth rate is higher than other measures of commer-
cial spending growth such as total medical expenditures 
(TME) per member. The difference between measures is 
discussed later in the chapter.
iv This excludes, for example, disabled or other enrollees 
receiving coverage on a fee-for-service basis and enrollees 
who are dually eligible for Medicare coverage and Mass-
Health benefits.
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Exhibit 2�2 Change in enrollment and per enrollee spending by major 
market segment, 2017 – 2018
Exhibit 2�3 Medicare spending growth per Medicare beneficiary by 
service category, Massachusetts and the U.S., 2017 – 2018
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In the commercial sector, spending grew 
3.9 percent in total while enrollment declined 
slightly, resulting in spending growth per enrollee 
of 4.6 percent– substantially above the benchmark
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SPENDING BY CATEGORY OF SERVICE
When analyzed by category of service, physician and 
other professionals’ spending grew by 4.5 percent in 
Massachusetts in 2018, representing the fastest-grow-
ing category of spending (see Exhibit 2.4). Within this 
category, physician spending growth was 2.8 percent, 
whereas spending for “other professional” services 
(such as care provided by a nurse practitioner or 
psychologist) grew more sharply at 8.4 percent. This 
represents an acceleration from growth of 5.9 percent 
from 2016 to 2017 and was driven by an 11.1 percent 
increase in the commercial sector. Some of the increase 
may reflect a growing presence of nurse practitioners 
in care delivery.v
Hospital outpatient spending grew by 3.8 percent in 
2018 – lower than the growth rate of 4.9 percent in 
2017, but still the fastest-growing category of spending 
over the 2016-2018 two-year period (8.9 percent). 
Increases in hospital outpatient spending can occur 
due to a number of factors, including price increases, 
volume increases, and shifts in care to outpatient 
settings from either higher-cost inpatient settings or 
lower-cost office-based settings. The HPC has previ-
ously reported on outpatient spending and continues 
this examination in Chapter 4 of this report.3
Hospital inpatient spending grew by 3.7 percent in 2018, despite 
continued decline in inpatient utilization (see Chartpack). 
Chapter 3 examines the underlying reasons for falling hospital 
volumes, as well as trends that prevented this decrease in utili-
zation from resulting in decreased hospital inpatient spending.
Prescription drug spending grew by 3.6 percent in 2018, slightly 
lower than in 2017, but still above the benchmark growth rate, 
continuing a multi-year trend. The slightly lower growth rate 
appears to be due in part to an increase in manufacturer rebates, 
which payers typically negotiate and receive through their 
pharmacy benefit managers (PBMs). For example, commer-
cial payers received 15.6 percent of pharmacy spending back 
v According to data from the Bureau of Labor Statistics (Occupation and 
Employment Statistics), the number of Nurse Practitioners employed 
in Massachusetts increased from 4,700 in 2013 to 6,200 in 2018. 
from manufacturers in the form of rebates in 2018, up from 
12.9 percent in 2017 and 10.7 percent in 2016.2 Not accounting 
for rebates, gross pharmacy spending grew by 5.8 percent in 
2018, up from 5.4 percent in 2017.2 Importantly, even though 
rebates may reduce payers’ expenses for prescription drugs, 
consumers typically pay their cost-sharing (deductibles and 
co-insurance) based on the list price of the drug and do not 
benefit directly from rebates.vi As a result of continued high 
spending and spending growth on prescription drugs that is 
not always commensurate with value, numerous state, federal, 
and commercial market initiatives have emerged in the last 
year to address affordability for patients and high drug prices 
overall (see Sidebar: Progress, Emerging Strategies, and New 
Challenges in Addressing Prescription Drug Spending).
vi Some payers and their PBMs are now offering point-of-sale (POS) 
rebates to reduce consumer out-of-pocket spending. A national survey 
found that about one in five large employers use POS rebates in their 
pharmacy benefit plans, and another 40 percent of large employers 
are considering POS rebates for 2021 and 2022. See Drug Channels, 
“Employers slowly warm to point-of-sale rebates – but must move faster 
for insulin.” Sept. 19, 2019. Available at: https://www.drugchannels.
net/2019/09/employers-slowly-warm-to-point-of-sale.html) 
Hospital inpatient spending grew by 
3.7 percent in 2018, despite continued 
decline in inpatient utilization
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Sources: Payer-reported total medical expenditure data to Center for Health Infor-
mation and Analysis and other public sources; HPC analysis of data from Center for 
Health Information and Analysis Annual Report, 2019
Exhibit 2�4 Rates of spending growth in Massachusetts in 2017 and 2018, 
by category
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SIDEBAR: PROGRESS, EMERGING STRATEGIES, AND  
NEW CHALLENGES IN ADDRESSING PRESCRIPTION DRUG SPENDING
Emerging legislative strategies to address 
prescription drug spending
The past year has seen a proliferation of proposals for addressing 
prescription drug spending in Massachusetts and other states, as 
well as at the federal level. Activities have focused on increasing 
affordability for patients, reviewing drug launch prices, moder-
ating the impact of drug price increases, and increasing pricing 
transparency.
In Massachusetts, the FY 2020 state budget gave authority to 
the Executive Office of Health and Human Services (specifically 
MassHealth) to negotiate directly with pharmaceutical manu-
facturers for supplemental rebates and charged the HPC with 
responsibility to investigate the manufacturer’s pricing for those 
drugs if a rebate agreement cannot be reached. Based on the 
results of the investigation, the HPC may ultimately determine 
whether the manufacturer’s pricing of the drug is unreasonable 
or excessive in relation to the drug’s value.
Several bills have recently been filed that would complement 
this new process. The Baker-Polito Administration filed a bill 
that would 1) expand the HPC’s review to include drugs with 
a financial impact to the total market in Massachusetts over a 
defined threshold, 2) address price increases through imposing a 
penalty on manufacturers that increase the price of a drug above 
an inflation-based threshold level, 3) increase state oversight of 
PBMs, and 4) establish requirements for pharmacists to ensure 
consumers pay the lowest cost for a prescription, among other 
provisions.4 In November, the Massachusetts Senate passed a 
bill with many of the same provisions, while also limiting out-of-
pocket spending on insulin for residents.5
Elsewhere in the U.S., 30 states passed at least 49 new laws 
regarding prescription drugs and affordability in 2019. Maine 
and Maryland created drug affordability review boards charged 
with recommending state action to address drugs that threaten 
patient affordability and state budgets. Both states passed laws 
with novel provisions: Maryland’s board is required to set upper 
payment limits, while Maine established a Canadian wholesale 
prescription drug importation program. Louisiana implemented a 
subscription model to treat hepatitis C in its Corrections Services 
and Medicaid program, in which the state will provide a specified 
budget to a single manufacturer to treat an unlimited number 
of cases. Innovative state financing models will become even 
more critical as new very high-cost therapies enter the market, 
as described in the section below. A number of states have also 
focused on generics drug prices. In May 2019, Massachusetts 
Attorney General Maura Healey joined a suit with Attorneys Gen-
eral from more than 40 states alleging a widespread conspiracy 
among 20 major drug makers to inflate and manipulate prices for 
more than 100 different generic medications that treat conditions 
including diabetes, cancer, multiple sclerosis, HIV/AIDS, and epi-
lepsy.6 The complaint alleges that the companies drove up prices 
for certain drugs by more than 1,000 percent. Federally, both 
houses of Congress and the Trump Administration have proposed 
a range of strategies to address drug affordability for patients, 
high launch prices, and price increases for the Medicare program.7
New challenges in financing gene therapy
Public and private payers also face new financial challenges to 
cover extremely high cost innovations in gene therapies. Cell 
and gene therapies modify a patient’s genes to address the 
patient’s health condition; many of these therapies are potentially 
curative. In 2019, the U.S. Food and Drug Administration (FDA) 
approved a gene therapy for spinal muscular atrophy, a rare child-
hood disorder. Zolgensma is a one-time potential cure; however, 
priced at $2.1 million per patient, it is also the most expensive 
treatment on the market, raising questions of whether that price 
is unreasonable, and how the health care system can finance 
innovations such as these even if the prices are justified. Novartis, 
the innovator, has proposed financing mechanisms to pay for 
the therapy over a period of time, and other new approaches to 
financing are being developed and tested, with some pioneered 
in Massachusetts. Cigna has created the Embarc Benefit Protec-
tion program, in which employers and other payers can pay a fee 
under $1 per member per month to gain protection for coverage 
of Zolgensma and other available gene therapies.8 Other insurers 
are also developing outcomes-based contracting models that 
tie price to clinical results. MIT’s NEWDIGS initiative focuses on 
developing a range of financing strategies to assist payers.9 Based 
on the pipeline of active clinical trials, an estimated 80 to 100 cell 
and gene therapies could be on the market by 2031.10 In an era 
of potential cures with gene therapy, public and private payers 
will require innovative and sustainable approaches to financing.
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COMPARISON TO 
NATIONAL TRENDS
In 2018, the Massachusetts total health care 
spending growth rate of 3.1 percent per capita 
was below the U.S. rate of 3.5 percent, continuing 
a consecutive nine-year trend of spending growth 
below the national growth rate (see Exhibit 2.5).
In the commercial sector, per member spending 
growth rates also continued to be below the 
national average (see Exhibit 2.6). Cumulatively 
from 2013 to 2018, these lower growth rates 
amount to commercial spending that was $7.2 
billion lower over this time period than would 
have been the case if growth rates matched the 
national average.
However, the measure of commercial spend-
ing in Exhibit 2.6 is total medical expenditures 
(TME), which does not include the administrative 
costs of private health insurance (e.g., insurer 
overhead, staffing and personnel, profit margin). 
These administrative costs have grown somewhat 
faster in Massachusetts than in the rest of the 
U.S. For example, while per capita TME grew 
by 12.9 percent in total from 2013 to 2018 in 
Massachusetts compared to the national rate 
of 24.7 percent (see Exhibit 2.7), commercial 
premiums (which do include these administrative 
costs) grew by 16.5 percent, slightly closer to 
the U.S. growth rate of 26.1 percent. And limit-
ing the comparison to only employer-sponsored 
insurance premiums (i.e. excluding the individual 
In 2018, the Massachusetts 
total health care spending 
growth rate of 3.1 percent per 
capita was below the U.S. rate 
of 3.5 percent, continuing a 
consecutive nine-year trend 
of spending growth below the 
national growth rate
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Exhibit 2�5 Annual growth in total health care spending per capita in 
Massachusetts and the U.S.
Exhibit 2�6 Annual growth in per capita commercial health care spending, 
Massachusetts and the U.S.
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market), the difference in premium growth between Massachu-
setts and U.S. average is even narrower. From 2013 to 2018, 
employer-sponsored single premiums grew by 18.3 percent 
in Massachusetts, while increasing by 20.5 percent nation-
ally. This difference is because individual market premiums 
in Massachusetts have grown more slowly than those in the 
employer-based market in Massachusetts, while the reverse is 
true in the rest of the US.
Exhibit 2�7 Cumulative growth in per capita TME, premiums, and 
employer-sponsored premiums in the Massachusetts commercial 
market compared to the U.S., 2013 – 2018
Notes: Fully-insured premiums are used for Massachusetts premium calcula-
tion. Private health insurance spending (which includes medical expenditures 
and net costs of private health insurance) is used to calculate average U.S. 
premium. U.S. data include Massachusetts.
Sources: Centers for Medicare and Medicaid Services, National Health 
Expenditure Accounts Personal Health Care Expenditures (national TME 
and premiums); Center for Health Information and Analysis annual reports 
(Massachusetts TME and premiums); Agency for Healthcare Research and 
Quality, Medical Expenditure Panel Survey (employer-sponsored premiums)
As shown in Exhibit 2.8, premiums for plans sold by the Mas-
sachusetts Health Connector, which are available to individuals 
and small employers, are the second lowest in the U.S. in recent 
yearsvii, while employer-sponsored insurance premiums in Massa-
chusetts ranked 4th highest in the country in 2018 and have not 
significantly narrowed the gap with the U.S. average since 2013.
vii Some of the reasons for the success of the Massachusetts Health Con-
nector include its offering a choice of comparable plans, a program of 
fixed-dollar premium and cost-sharing subsidies that incentivizes low 
premiums from participating carriers and then concentrates enrollment 
in these low-cost plans, and a suite of policies that promote continuous 
coverage, such as an individual coverage mandate and streamlined 
special enrollment periods for individuals in need of coverage outside 
open enrollment. Some of these are discussed on p.69 of the HPC’s 
2016 Annual Health Care Cost Trends Report. 
Exhibit 2�8 Annual premium for single coverage in the employer 
market and average annual unsubsidized benchmark premium for 
a 40-year-old in the ACA Exchanges, Massachusetts and the U.S., 
2013 – 2019
Notes: U.S. data include Massachusetts. Employer premiums are averages 
based on a large sample of employers within each state. Exchange data 
represent the weighted average annual premium for the second-lowest 
silver (Benchmark) plan based on county-level data in each state. From 
2013 to 2017, the exchange premiums shown reflect a 70% actuarial value, 
less generous than the average employer plan shown (typically around 
85%), which explains some of the difference between the two lines. In 2018, 
the cost of silver plans rose due to carriers having to incorporate the cost 
of cost sharing reductions for some silver tier enrollees which the federal 
government had been funding. Exchange and group market premiums do 
not differ for the same plan.
Sources: Kaiser Family Foundation analysis of premium data from healthcare.
gov (marketplace premiums 2014-2019); Agency for Healthcare Research and 
Quality, Medical Expenditure Panel Survey (commercial premiums 2013-2018)
If premium growth trends also included patient cost-sharing, 
the increase in health care spending would be even larger. While 
Massachusetts premiums grew 16.5 percent from 2013 to 2018, 
cost sharing grew by 30.4 percent and combined growth of the 
two was 17.7 percent.viii This is consistent with the continued 
rapid rise in the percentage of Massachusetts residents with 
high-deductible plans (from 24.5 percent in 2016 to 31.5 percent 
in 2018),2 which are often embraced by employers as a means 
to keep premium growth down. Thus, with relatively rapid 
increases in both premiums and deductibles, compared to modest 
increases in average wages and salaries, Massachusetts residents 
are increasingly facing health care affordability challenges.
viii Cost-sharing and premiums would be expected move in opposite 
directions; all else equal, increasing deductibles will reduce premiums.
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AFFORDABILITY OF CARE
As noted in CHIA’s 2019 Annual Report, health insurance 
premiums and cost-sharing in Massachusetts grew roughly 
twice as fast as worker wages and salaries and the rate of 
inflation between 2016 and 2018 – meaning an ever-larger 
share of the earnings of families with private health insurance 
are devoted to health care. For a typical family in Massachu-
setts with coverage through an employer, total health care 
spending amounted to an average of $2,091 per month when 
including health insurance premiums (employer and employee 
contributions) and out-of-pocket health care spending.ix Some 
families spent much more – for approximately 10 percent of 
the population, spending exceeded $3,000 per month.x Much 
of this spending on health care is not readily visible – employ-
ers pay for covered workers’ (and their families’) health care 
spending out of their total pool of compensation. When more 
compensation is paid in the form of health care spending, less 
is paid in worker wages and salaries.
ix This total is the sum of 1) $1,871 in average family health insurance 
premiums (including employer and employee contributions) as estimated 
by the Medical Expenditure Panel Survey – Insurance Component 
administered by the Agency for Healthcare Research and Quality, 2) 
$221 based on the ratio of cost-sharing to premium spending according 
to data from the CHIA 2019 Annual Report, and 3) $53, an estimate of 
over the counter and other sources of health care spending not covered 
by insurance from the Current Population Survey, Annual Supplement. 
x This calculation is based on the ratio in the Medical Expenditure Panel 
Survey of the 90th percentile of premium spending in Massachusetts 
($29,333) to the mean premium in Massachusetts ($20,603) over 
2016 to 2018.
Including employer premium spending, the HPC estimates that 
nearly 40 cents of every additional dollar earned by Massa-
chusetts families between 2016 and 2018 was spent on health 
care (see Exhibit 2.9).
Massachusetts’ median family income grew over this period 
(2016 to 2018) from $95,207 to $101,548. At the same time, 
premiums for employer-sponsored insurance grew almost 
$3,000 per year, from $18,955 to $21,801. In total, a median 
family was compensated an additional $712 monthly by their 
employers in 2018 versus 2016, yet of this total, $277 was 
absorbed by additional health care spending ($184 in the form 
of added employer contributions to health care, $53 in employee 
premium spending and $40 in additional out-of-pocket spending 
on health care). The $277 in additional health care spending 
exceeded the portion families took home as additional dispos-
able income ($270) after paying state and federal taxes ($165). 
Given the fact that most employers are not able to offer multiple 
plans, many families with employer-sponsored coverage have 
little choice but to continue to see a growing share of their 
disposable income devoted to health care.xi, 2
xi Most employers do not offer employees a choice of plans (Massa-
chusetts Health Policy Commission, Annual Cost Trends Report, 
2016). Further, premiums do not tend to vary across insurers by a 
large amount, and when employers require employees to pay a set 
percentage of the premiums (say, 20 percent), then any employee 
savings from choosing lower-cost plans is drastically reduced. On the 
other hand, several plans available on the Massachusetts Connector 
cost more than one-third less than most employer-based plans and any 
enrollee subsidies are fixed (not dependent on the plan chosen) - thus, 
enrollees fully pocket any premium savings.
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Notes: Data represent Massachusetts families who obtain 
private health insurance through an employer. Massa-
chusetts median family income grew from $95,207 to 
$101,548 over the period while mean family employ-
er-sponsored insurance premiums grew from $18,955 to 
$21,801. Compensation is defined as employer premium 
contributions plus income as recorded in the American 
Community Survey and is considered earnings. All pre-
mium payments are assumed to be non-taxable. Tax 
figures include income, payroll, and state income tax.
Sources: HPC analysis of Agency for Healthcare Research 
and Quality, Medical Expenditure Panel Survey Insur-
ance Component (premiums); Census Bureau, American 
Community Survey 1-year files (income), and Center for 
Health Information and Analysis 2019 Annual Report 
(cost-sharing)
Exhibit 2�9 Allocation of the increase in monthly compensation between 2016 and 2018 for a median Massachusetts family 
with health insurance through an employer
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Recent changes in benefit design could also expose some 
consumers to additional costs. For example, employers are 
increasingly adopting spousal surcharges, a fee added to an 
employee’s premium for electing to insure a spouse who is eli-
gible for coverage through their own employer. Almost one in 
four Massachusetts employees were subject to these surcharges 
in 2018, double the percentage in 2015 (see Exhibit 2.10).xii
Exhibit 2�10 Percent of employees who pay a higher premium 
contribution if their spouse is eligible for coverage through their 
own employer, 2015 and 2018
Sources: HPC analysis of Agency for Healthcare Research and Quality, 
Medical Expenditure Panel Survey
Finally, the growing financial burden of health care is felt 
particularly acutely by lower- and middle-income households 
with employer-based coverage.xiii This is partly because these 
families have less available income after paying for health care. 
Twenty three percent of middle class families in Massachusetts 
with employer coverage devote more than a quarter of all 
earnings to health care.xiv These families are more likely to be 
non-white (29.4 percent), lack a college degree (62.9 percent), 
be a single parent (50.1 percent), have a disability or activity 
xii Data obtained via special table request from the Agency for Healthcare 
Research and Quality, November 5, 2019.
xiii This is also true for individual market enrollees not eligible for subsidies, 
though they enjoy a wider range of plan choices and savings opportuni-
ties than most individuals who obtain coverage through their employers.
xiv HPC’s analysis of data from the CPS Annual Social and Economic 
Supplement (ASEC), 2016-2018 and Agency for Healthcare Research 
and Quality (AHRQ) Medical Expenditure Panel Survey (MEPS), 
2016-2018. Estimates are based on a three-year average of middle 
class families from 2016-2018. Middle class definition is based on 
General Social Survey (GSS) occupational prestige scores. 
limitation (14.7 percent) and have worse health 
in general (31.8 percent).xv Furthermore, these families often 
must pay a higher portion of the insurance premium than 
higher-income families. In recent years in Massachusetts, 
employees of lower-wage firms were charged significantly more 
for their portion of health insurance premiums than employees 
at other firms, on average.xvi This disparity reached almost 
50 percent by 2018: required premium contributions averaged 
$683 per month for family coverage for employees of firms 
in the lowest average wage quartile versus $459 per month 
for employees at higher-wage firms. Though it is unclear why 
this trend has emerged, lower-wage firms may struggle more 
than other firms to afford the high cost of coverage for employ-
ees, and particularly their families, and may therefore encourage 
those employees to seek other coverage options.
Overall, while health care spending growth in Massachusetts 
was at the benchmark level in 2018, commercial spending 
growth per enrollee and commercial premiums exceeded the 
benchmark as well as growth in earnings for Massachusetts 
residents, making health care increasingly unaffordable, partic-
ularly for lower- and middle-income residents with insurance 
through their employers. The further analysis and discussion 
in this report and its recommendations are oriented toward 
improving the affordability of health care for all residents while 
maintaining high quality and accessibility of care.
xv “College degree” was defined as having a B.A. or higher degree in the 
family. Single-parent families are those in families who did not report 
being in a married couple family (male or female reference person). 
Disability or activity limitation was defined as difficulty walking 
or climbing stairs, dressing or bathing, hearing, seeing, or having a 
health problem or a disability which prevents work or limits the kind 
or amount of work they can perform. “Worse health” was defined as 
those reporting a health status “poor,” “fair” or “good.”
xvi Data from the Agency for HealthCare Research and Quality, Medical 
Expenditure Panel Survey – Insurance Component. 
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Twenty three percent of middle class 
families in Massachusetts with employer 
coverage devote more than a quarter of all 
earnings to health care
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CHAPTER 3: 
 HOSPITAL INPATIENT 
SPENDING AND UTILIZATION
Hospital inpatient spending has continued to grow despite 
a constant or declining number of hospital stays; among 
commercially-insured patients, spending per inpatient stay 
grew 5.2 percent annually between 2013 and 2018, from 
$14,500 to $18,700.
5.2%
Factors such as population aging, changes in underlying 
disease prevalence or health status, or shifting of healthier 
patients out of hospital settings do not explain growing patient 
acuity or risk scores. Evidence suggests that a considerable 
portion of the change is due to hospital coding practices.
Commercial inpatient volume declined 9.3 percent between  
2014 and 2018. 
The decline in inpatient hospital stays was almost entirely due 
to fewer maternity-related discharges and fewer scheduled 
admissions, as opposed to admissions from the emergency 
department. 
9.3%
One factor leading to higher spending per stay is increasing 
acuity among inpatient stays. Acuity grew by more than 10 
percent from 2013 to 2018 for all hospitalized patients; patient 
risk scores grew by 11.7 percent over this period. 
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CHAPTER 3:  
HOSPITAL INPATIENT  
SPENDING AND UTILIZATION
In 2018, hospital spending accounted for 41 percent of total 
health care expenditures (THCE) in Massachusetts, with just 
over half of that spending originating from inpatient stays and 
the remainder from hospital outpatient departments. Both 
inpatient and outpatient care accounted for 47 percent of 
THCE growth between 2017 and 2018. The HPC has explored 
various aspects of hospital spending in previous Cost Trends 
Reports, including price variation in maternity episodes, the 
composition of hospital outpatient spending, and inpatient 
price growth. This chapter focuses on additional dynamics 
underlying hospital inpatient spending growth while Chapter 4 
explores growth in commercial outpatient spending in detail, 
particularly focusing on trends in outpatient surgery.
HOSPITAL INPATIENT TRENDS:  
SECTIONS 3�1 AND 3�2
Hospital inpatient spending grew 3.7 percent in Massachusetts 
from 2017 to 2018, despite a slight decline in the number 
of inpatient stays (see Chartpack) – indicating that spend-
ing growth was driven by higher spending per stay, rather 
than more hospital stays. In seeking to understand growth 
in spending per inpatient stay, the HPC has identified three 
important concurrent trends in the commercial inpatient market 
in Massachusetts: 1) rising prices paid for a given stay, 2) rising 
reported severity of illness (acuity) of hospitalized patients, 
and 3) declining number (volume) of admissions.i,1 Section 3.1 
explores the second trend in detail. Section 3.2 focuses on the 
third trend.
i The HPC’s 2018 Cost Trend Report also focused in detail on rising 
prices for a given admission.
SECTION 3�1: CHANGES IN INPATIENT 
SEVERITY OF ILLNESS
Severity of illness (patient acuity) refers to how sick a hospital-
ized patient is, as reflected in hospital administrative data. The 
HPC has observed steadily rising patient acuity in a number 
of contexts. In a previous analysis of commercially-insured 
hospitalized patients observed in the Massachusetts All-Payer 
Claims Database (APCD), the HPC found the average acuity 
of such patients rose 4.2 percent between 2014 and 2016.1 
Separately, the HPC found that the proportion of “high acuity” 
(as opposed to “community-appropriate”) discharges in the 
Commonwealth increased from 56 percent of all discharges 
to 62 percent of all discharges across all payers between 2010 
and 2017.2 Finally, the HPC has observed a steady rise in 
patient risk scores over time, amounting to an 11.7 percent 
increase between 2013 and 2018 (see Sidebar: Increasing Risk 
Scores and Health-Status Adjusted TME). The HPC has found 
that only a small portion of this increase can be explained by 
demographic trends such as the age/sex mix of the population 
or changes in disease prevalence. This increase in acuity has 
important policy implications for the Commonwealth. This 
chapter explores in more detail the observed increase in acuity 
among hospital inpatients.
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SIDEBAR: INCREASING RISK SCORES AND HEALTH-STATUS ADJUSTED TME
The “risk score” is a measure designed to estimate an individual’s 
expected health care spending over the course of a year based 
on patient characteristics – most commonly age, sex, and diagno-
ses. It is typically computed by health insurance companies and 
used throughout health care payment and quality measurement 
systems to ensure that providers and payers are neither inap-
propriately penalized for having sicker and more costly patients, 
nor inappropriately motivated to avoid them. For example, the 
Affordable Care Act state-based marketplaces include a provision 
whereby insurers with a healthier mix of patients must transfer 
funds to insurers with a sicker mix of patients in order to balance 
costs and reduce incentives of plans to profit by enrolling dis-
proportionately healthy individuals.3 Risk-based arrangements 
(employed by many alternative payment methods and Medicare 
Advantage), whereby providers care for a fixed set of patients over 
the course of a year and gain or lose bonus payments based on 
their total costs of care, also tend to include payment adjustments 
for patient risk scores – with the similar aim of compensating 
providers who may care for a patient population with greater 
needs. In these cases, payments received by providers or payers 
to care for these populations are typically directly proportional 
to risk scores – a 10 percent higher risk score may translate to 
a 10 percent higher payment.4
Commonly reported quality measures such as readmissions rates 
and hospital mortality rates are also typically risk-adjusted using 
administrative claims data. Furthermore, the HPC’s consideration 
of whether to require a performance improvement plan, one of the 
key accountability provisions of Chapter 224, uses risk scores as 
part of the calculation of “health-status-adjusted total medical 
expenditures” to determine whether providers’ or plans’ spending 
growth exceeds the benchmark.
Risk scores are typically calculated via complex, proprietary 
software that combines data on observed patient spending with 
other patient data to estimate how much a patient with a given 
set of medical diagnoses, age, gender and other factors might 
be expected to incur in medical costs. For a full population, risk 
scores are expected to be relatively stable over time because 
the health of entire populations changes slowly. However, this 
has not been the case in Massachusetts in recent years (see 
Exhibit 3�1�1).
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Notes: Several payers are omitted from the graph due to data anomalies. The insurers shown represent more 
than 70 percent of the commercial market in Massachusetts. All risk scores are normalized to 1.0 in 2013.
Sources: HPC analysis of Center for Health Information and Analysis Annual Reports: Total medical 
expenditures (TME) databooks, 2016-2019
Exhibit 3�1�1 Change in commercial member risk scores over time, by payer, 2013 – 2018
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Among the six insurers’ commercial populations, risk scores 
rose between 5 and 21 percent, with an overall average increase 
of 11.7 percent (2.2 percent per year). It is implausible that the 
health of the Massachusetts population has truly worsened to 
this extent. According to the Affordable Care Act’s risk adjustment 
system noted earlier, it would take an additional 428,000 commer-
cially-insured Massachusetts residents with complex diabetes 
or 920,000 (more than 20 percent of the commercially-insured 
population) with cerebral palsy to generate a risk score increase 
of that magnitude.5
Though some have suggested the increase in risk scores could 
be due to population aging,6 the HPC found that, while the pop-
ulation of Massachusetts is indeed aging (and older residents 
incur greater medical expenditures), aging has a minor impact on 
the growth in risk scores in the commercial population. Aging is 
modest within the commercially-insured population. For example, 
the percentage of commercially-insured Massachusetts residents 
who are between the ages of 55 and 64 (where expenditures 
are several times higher than for younger residents) grew from 
17.8 percent to 18.2 percent between 2015 and 2018. In all, when 
combined with patterns of spending for various age and gender 
groups, the observed demographic changes between 2015 and 
2018 among Massachusetts’ privately-insured population would 
be expected to increase commercial spending by 0.5 percent 
in total – a small fraction of the growth in risk scores (which are 
proportional to expected spending) over this period.ii
The HPC also analyzed self-reported survey data regarding dis-
ease prevalence in Massachusetts through 2016 (the most recent 
year available) from the Centers for Disease Control, which is less 
prone to changes in clinical or health care administrative practic-
es.7 The HPC found that between 2013 and 2016, the prevalence 
of arthritis and diabetes increased by 0.8 and 0.4 percentage 
points, respectively, while the prevalence of asthma and chronic 
obstructive pulmonary disease (COPD) decreased by 1.2 and 
0.4 percentage points. Life expectancy in Massachusetts did 
not change over this time period.8 And, while the opioid epidemic 
is indeed severe and impactful, it has not made an appreciable 
impact on overall commercial risk scores.
Insofar as changes in risk scores reflect true changes in the 
health of the population, they are a critical tool for fairly adjusting 
payment and quality measurement and to ensure that payers and 
providers under risk are not encouraged to avoid sicker patients. 
However, to the extent that increasing risk scores reflect other 
dynamics, such as changes in coding, the accuracy of risk-ad-
justed quality or payment systems may be compromised.
ii While Exhibit 3.1.1 displays risk score growth from 2013 to 2018, 
data on the demographics of the commercially-insured population in 
Massachusetts were only available to the HPC from 2015 to 2018; 
thus, the aging trend was compared to the risk score trend from 2015 
to 2018 only. 
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The acuity of hospitalized patients is a critical factor in hos-
pital spending because of how hospitals are paid. The vast 
majority of hospital stays, including those covered by Medicare, 
MassHealth and commercial payers, are classified and paid for 
according to the diagnosis-related group (DRG) system.iii The 
system was developed by Medicare in 1983 in response to rising 
payments which had previously been based on hospitals’ own 
reported costs of care. The new model instituted a system of 
fixed payments for a given hospital stay and led to a dramatic 
reduction in annual hospital spending growth (from 5.6 percent 
from 1975-1983 to 2.1 percent from 1983-1997) in part due to 
this change in payment method.9,10 Today most insurers have 
adopted this system (Medicare Severity Diagnosis-Related Group, 
MS-DRG) or the related All Patient Refined Diagnosis-Related 
Group (APR-DRG). The APR-DRG system is similar to the 
MS-DRG system, but calibrated for a non-elderly population.
Both of these payment systems assign a diagnosis group (e.g. 
“pneumonia”) to a given hospital stay along with a severity level 
(e.g. “with major complications”) and assign a “weight” to 
the DRG/severity combinationiv that is intended to correspond 
with the expected resources needed to treat the patient (see 
Sidebar: DRG Systems, DRG Weights, and Prices).v Critically, 
this weight is applied as a direct multiplier to the payment 
the hospital receives for the stay. The average weight, which 
hospitals often refer to as the “case-mix index,” is the measure 
of acuity tracked in this chapter.
The assignment of a DRG and a severity level for a hospital 
stay is made via software algorithms based on patient diag-
noses and clinical data entered into the patient’s record over 
the course of the stay by clinicians. These clinical data are 
typically adjusted or refined after the stay into medical billing 
language by hospital administrative staff (e.g. registered nurses 
or medical coding technicians), often in consultation with the 
clinicians who treated the patient.
This payment system was designed to reduce the degree to 
which payment depends on hospitals’ reported costs, which 
iii There are some exceptions. Some insurers pay a fixed amount per 
inpatient day (“per-diem”) and payers sometimes make other adjust-
ments, such as for very long stays. See Technical Appendix.
iv In the MS-DRG system, each DRG is itself a diagnostic group with or 
without complication/ major complications, while in the APR-DRG 
system each DRG has four severity levels.
v The original DRGs had two or one severity levels, but in 2007, these 
were expanded such that most DRGs now have three severity levels 
under the MS-DRG system or four under the APR-DRG system. See: 
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/
AcuteInpatientPPS/IPPS-Regulations-and-Notices-Items/CMS1228401.
html
hospitals have some ability to control, in favor of standard 
measures of resources need to treat inpatients. Nevertheless, 
the current system is based on diagnoses, co-morbidities, and 
clinical indicators of severity, all of which can also be influenced 
by clinical judgment and hospital technology and processes. 
Each patient is unique, and, particularly for certain symptoms, 
physicians and other personnel exercise discretion as to the 
presence of certain co-morbidities, symptom severity, and 
appropriate classification of a given patient presentation.11,12
While there can be clinical benefits to more complete doc-
umentation of patients’ health status and histories in their 
medical records, hospitals also have a financial interest in 
classifying a given patient into the highest-paying category 
and in understanding the algorithms at work that translate 
clinical data into DRG/severity classifications.vi Prior litera-
ture has shown that hospitals are able to modify their coding 
practices to increase payments while the underlying severity 
of the patient population remains the same.13,14,15 Furthermore, 
advanced electronic health records systems such as EPIC can 
facilitate hospitals’ ability to increase payments (indeed, they 
often advertise this ability directly) by auto-populating the 
patients’ record with prior diagnoses, for example, which can 
enable coding of the DRG into a higher-severity category.16,17 
Several research studies have found a link between adoption 
of advanced health IT in hospitals with higher reported patient 
acuity, although one study did not.18,19,20
Some increases in patient acuity could also arise from true 
changes in patient health status or a selective shifting of health-
ier patients from inpatient to outpatient settings. Given the 
noted observations of increasing patient acuity, particularly 
in the inpatient setting, the HPC sought to characterize and 
understand changes in patient acuity, the underlying causes of 
those trends, and their implications for health care spending 
in the Commonwealth.
vi Additional efforts on the part of hospital clinicians and administrative 
staff directed toward maximizing reimbursements based on coding 
also represent time, effort and attention that could otherwise be spent 
more directly toward optimizing patient care and health outcomes.
Prior literature has shown that hospitals are 
able to modify their coding practices to increase 
payments while the underlying severity of the 
patient population remains the same
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SIDEBAR: DRG SYSTEMS, DRG WEIGHTS, AND PRICES
Different DRG Systems
There are two major diagnosis-related group (DRG) systems used 
by the U.S. health care system: Medicare Severity (MS) and All 
Patient Refined (APR). The MS-DRG system groups inpatient stays 
into 754 DRGs (for example, pneumonia), most of which (but not 
all) are further bi- or tri-furcated into different levels of severity 
“without complications,” “with complications,” and “with major 
complications/comorbidities.” This system is used by Medicare 
and about 17 percent of the commercial market in Massachu-
setts.vii The APR-DRG system groups all inpatient stays into 315 
DRGs each having four severity levels, 1 through 4, with 4 being 
the most severe. The APR-DRG system is used by MassHealth 
and the majority of the commercial payers in Massachusetts. The 
analyses in this report use both DRG systems.viii
Payments are directly proportional to 
DRG weights
Under either system, the resulting payment the hospital receives 
is produced by multiplying a base rate by the DRG weight, where 
the DRG weight is defined by the DRG and the severity level. For 
example, MassHealth payment for COPD admission in 2018 would 
be equal to its base rate ($12,472) multiplied by the weight for a 
given severity level (weights are shown in Exhibit 3�1�2).
Updates to classifications and weights can 
reduce the impact of coding intensity
All groups are updated annually to reflect changes in technology 
and resource use associated with treating certain conditions rela-
tive to other conditions. To produce the updates, analysts examine 
patterns of resource use for a DRG/severity combination and 
adjust weights accordingly.ix For example, if COPD/severity level 
4 becomes more costly to treat due to use of a new technology, 
the weight would be adjusted upward. Conversely, if increasingly 
healthy patients are being coded as COPD/severity 3 compared 
to prior years, with commensurately lower costs of treatment, 
vii Based on the HPC analysis of data in Center for Health Information 
and Analysis. Payer-reported Relative Price. Aug. 2019.
viii Parts of this report were produced using proprietary computer software 
created, owned and licensed by the 3M Company. All copyrights in and 
to the 3M APR™ Software, and to the 3M APR™DRG classification 
system(s) (including the selection coordination and arrangement of 
all codes) are owned by 3M. All rights reserved.
ix To produce the updates for MS-DRG, CMS updates the DRG system 
based on multiple factors including: changes in medical practice, 
technology, and the variation in cases within a DRG. For more 
information see: https://oig.hhs.gov/oei/reports/oei-09-00-00200.pdf.
then the weight would be adjusted downward relative to other 
DRGs. For example, as shown in Exhibit 3�1�2, when MassHealth 
updated its weights in 2018, the weight for COPD/severity level 4 
shifted downward. Although MassHealth adjusted its base rates 
such that total hospitals payments were unchanged, the payment 
differential between COPD level 3 and COPD level 4 was reduced 
from 114 percent to 82 percent.
Exhibit 3�1�2 COPD APR-DRG weights for each severity level; Mass-
Health 3M APR™DRG versions 30 (2015 – 2017) and version 34 
(introduced in 2018)
Notes: Version 30 was used between 2015 and 2017. In 2018 MassHealth 
adopted version 34.
Sources: 3M APR™DRG classification system v30.0, v34.0; Acute Hospital 
MassHealth DRG Weights
Unlike MassHealth and Medicare which update DRG weights more 
frequently, many commercial payers use the same DRG versions 
and weights for many years, in part due to the administrative 
burden of making system changes. At the beginning of 2018, all 
large Massachusetts insurers continued to use an early APR-DRG 
system version (3M APR™DRG v30.0 or earlier versions), even 
though an updated version (version 34) had been available since 
2016 and had been implemented by MassHealth.21
These weight updates, on average, tend to somewhat offset the 
effects of coding the same patients into higher severity levels; 
for example, the 7.9 percent weight increase the HPC observed 
for Medicare patients, which incorporates annual weight updates, 
would have been even higher if Medicare had not updated the 
weights between 2013 and 2018.
Severity 4Severity 3Severity 2Severity 1
0.44 0.40
0.55
0.48
0.74
1.58
1.13
0.62
Version 30 Version 34
Severity 4Severity 3Severity 2Severity 1
0.44 0.40
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0.74
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Version 30 Version 34
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In order to analyze trends in inpatient acuity, the HPC compiled 
all inpatient discharges from the CHIA Hospital Inpatient 
Discharge Database from fiscal year 2013-2018. CHIA applies 
the same grouping algorithm used by payers to assign each 
inpatient discharge both an APR-DRG and MS-DRG category 
and severity level (see Technical Appendix for additional 
details). To gain insight into whether observed acuity changes 
were related to changes in underlying patient health, the HPC 
tracked several additional indicators of patient acuity simul-
taneously present in the discharge data including information 
on the length of stay (LOS), number of days in the intensive 
care unit (ICU), cardiac care unit (CCU), or neonatal intensive 
care unit (NICU).x
TRENDS IN PATIENT ACUITY OVER TIME
Inpatient acuity as measured by the DRG weight under both 
the APR-DRG and MS-DRG system increased dramatically 
between 2013 and 2018, by 13.7 percent and 10.8 percent, 
respectively (see Exhibit 3.1.3).xi At the same time, trends in 
patient length of stay and use of intensive care do not suggest 
x This mirrors approaches taken by other researchers cited in this chapter.
an increase in underlying patient acuity. Use of all types of 
intensive care declined.xii The increase occurred across all 
hospital types and systems (not shown), though there was 
some variation in the extent of the increase across hospitals.
Increases in DRG weight as observed in Exhibit 3.1.3 can occur 
due to shifts from low- to high-severity classifications within a 
given DRG (e.g. from COPD without complications to COPD 
with complications) or from shifts in assignment from one DRG 
to another, related DRG. We find evidence for both types of shifts.
xi Analysis uses 3M APR™DRG classification system v30.0 using 
MassHealth weights. In a sensitivity analysis, the HPC used 3M 
APR™DRG v30.0 commercial weights, which had a similar trend 
to MassHealth weights over the time period.
xii As a further test, the HPC examined these same metrics by major 
diagnostic category. These trends remained similar across the vast 
majority of categories with few exceptions. The HPC also conducted 
a sensitivity test regarding the measure of intensive care days which 
included use of intermediate ICU days to the measure. They were 
excluded from the core measure because intermediate ICUs treat 
lower severity patients than regular ICUs. For example, see Sjoding, 
MW et al. Rising Billing for Intermediate Intensive Care, American 
Journal of Respiratory and Critical Care Medicine 2016. Even after 
incorporating intermediate ICU use, there was still a decline in all 
ICU, CCU, NICU, and intermediate ICU use over the study period.
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Notes: ICU = intensive care unit; CCU = cardiac care unit; NICU = neonatal intensive care unit. This curve represents 
days in any of these settings combined.
Sources: HPC analysis of Center for Health Information and Analysis Hospital Inpatient Discharge Database, 
FY2013-FY2018; MS-DRG classification system for each year (weights updated each year), 3M APR™DRG clas-
sification system v30.0 using MassHealth weights (weights held constant)
Exhibit 3�1�3 Percent increase in overall DRG weight, patient length of stay, and use of intensive care settings, 2013 – 2018
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INCREASES IN SEVERITY OF DRG LEVELS
Across inpatient stays for all payers in the Commonwealth, the 
HPC observed a substantial shift from low-severity to high-se-
verity DRGs (see Exhibit 3.1.4). In the APR-DRG system, 
the number of severity level 4 (most severe) discharges grew 
74 percent over this time period, the number of level 3 DRGs 
increased 26 percent, the number of level 2 discharges declined 
5 percent, and the number of severity level 1 DRGs declined 
20 percent. Under the MS-DRG system, the highest-severity 
DRGs increased 45 percent while the lowest-severity DRGs 
declined 14 percent. The coding of additional conditions 
(secondary diagnoses) that might be in patients’ records could 
explain some of the increases. For example, in 2018, 95 percent 
of inpatient discharges has 5 or more diagnosis codes, a sub-
stantial increase from 77 percent in 2013.
One possible explanation for the rise in inpatient acuity is that 
low-acuity discharges are disproportionally being shifted to 
outpatient settings. If this were the case, one would expect 
to see fewer low-severity discharges and the same number 
of high-severity discharges. While this may be true for some 
diagnoses (shifting is explored further in Chapter 4) we find 
that overall, the number of discharges coded as high-severity 
(levels 3 or 4) has increased significantly, even more than the 
drop in low-acuity discharges. As shown below in Exhibit 3.1.4, 
from 2013 to 2018, the number of low-severity discharges 
dropped by 63,000 while the number of high-severity dis-
charges increased by 66,000.
63,000 DISCHARGES +66,000 DISCHARGES
With major
complications
With
complications
Without
complications Severity 4Severity 3Severity 2Severity 1
MS-DRG APR DRG
-14%
45%
-20%
-5%
26%
74%
-1%
40,000 DISCHARGES +51,000 DISCHARGES
Notes: APR-DRG level 1 is the least severe and level 4 is most severe. The MS-DRG analysis only includes the subset of 
DRGs that have three complication levels as shown.
Sources: HPC analysis of Center for Health Information and Analysis Hospital Inpatient Discharge Database, FY2013-FY2018; 
MS-DRG classification system (weights updated each year), 3M APR™DRG classification system v30.0 (weights held constant)
Exhibit 3�1�4 Change in number of hospital admissions at each severity/complication level for all payers, 2013 – 2018
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The increase in high-severity coding for chronic obstructive 
pulmonary disease (COPD) illustrates this trend. COPD is 
an inflammatory lung disease that causes breathing difficulty, 
chest tightness, and a chronic cough among other symptoms. 
In 2013, two out of every five inpatient stays related to COPD 
were coded at one of the highest two severity levels (level 3 
or 4). By 2018, that proportion had increased to two of every 
three (see Exhibit 3.1.5). Again, this increase is not due to 
lower-severity cases being treated outside of the hospital while 
only higher-severity cases remain – the absolute volume of the 
highest two severity levels increased by over 3,000 discharges 
over this period.xiii Overall, the increase in acuity (weight) 
for all patients with COPD DRGs over this time period was 
17 percent, while length of stay for these patients declined by 
3 percent and intensive care days fell sharply, by 15 percent. 
As noted in Exhibit 3.1.5, a shift from level 3 to level 4 results 
in almost a doubling of revenue to the hospital due to the 
difference in weights between 3 and 4.
xiii In 2013 there were 17,818 discharges with an APR-DRG for COPD; 
7,157 of these discharges were severity level 3 or 4. In 2018 there 
were 16,017 discharges with an APR-DRG for COPD; 10,294 of 
these discharges were severity level 3 or 4.
INCREASES IN ACUITY DUE TO SWITCHING 
TO A MORE SEVERE DRG: SEPTICEMIA 
CASE STUDY
Acuity may also be increasing due to shifts from one DRG 
to a different, but related DRG (for example, from asthma 
to COPD). One example is in the diagnosis of septicemia 
or sepsis, the body’s overwhelming response to an infection, 
which can become life-threatening if not treated promptly.xiv, 22 
This disease can be underdiagnosed, leading to tissue damage, 
organ failure, and death. Recent sepsis awareness campaigns 
introduced nationally and locally seek to improve the public’s 
understanding of the disease, and CMS has implemented a 
national intervention protocol and quality measure aimed at 
improving early detection and treatment.23, 24 At the same time, 
some have raised concerns that over-labeling more minor or 
marginal cases as septicemia can lead to unnecessary overtreat-
ment including overuse of antibiotics and unintended harm.25
xiv Sepsis is the body’s overwhelming response to infection while septice-
mia refers to a bacterial infection that has entered the blood stream, 
also known as bacteremia. For administrative coding and billing 
purposes, the 3M APR™DRG is labelled as “septicemia and dissem-
inated infections.” For this reason, in the remains of this section we 
will refer to “septicemia” since the primary focus is on coding with 
one exception (i.e., sepsis awareness campaigns). 
201820172016201520142013
Distribution of severity level for COPD 
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sification system v30.0; Acute Hospital 
MassHealth DRG Weights for 2018
Exhibit 3�1�5 Distribution of COPD severity levels, all-payer, 2013 – 2018, and payment for each severity level, 2018
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Septicemia shares some symptoms with and may develop from 
a number of other conditions, including pneumonia, urinary 
tract infection (UTI), and cellulitis. Patients in the hospital 
with some of these conditions should be monitored to ensure 
they do not develop septicemia. However, due to this overlap 
the same patient with the same symptoms could plausibly be 
coded as having either pneumonia or septicemia, depending 
on how the patient’s symptoms and diagnoses are recorded 
by clinicians and handled by medical coders.26, 27, 28 Financial 
incentives tend to encourage hospitals to code borderline cases 
as septicemia because of the higher weight, and hence, higher 
payment. In 2016, the average Massachusetts commercial 
payment for septicemia was $22,618, compared to $11,911 
for pneumonia, $9,016 for cellulitis, and $9,193 for UTI (see 
Exhibit 3.1.6).xv
xv For example, one coding blog offers medical coders advice on how to 
increase revenue by coding sepsis rather than other similar conditions. 
https://www.aapc.com/blog/31689-sepsis-and-sirs-in-icd-10-cm/
As shown in Exhibit 3.1.6, the number of inpatient stays coded 
with the septicemia DRG increased by 22,806 cases from 
2010 to 2018, while those with pneumonia, UTI, cellulitis, 
fever, respiratory, GI or post-operative infections combined 
declined by 12,353. Given the efforts to increase recognition 
of septicemia, this increase likely includes patients for whom 
the diagnosis of septicemia reflects receipt of appropriate 
treatment for this serious condition. The magnitude of the 
increase, however, suggests that coding of borderline cases 
as septicemia also contributes to the trend. Indeed, infectious 
disease doctors and researchers have urged adoption of a 
more stringent definition of septicemia instead of the current 
definition used in the CMS sepsis quality measure.xvi Adoption 
of a more targeted definition could both improve treatment 
and enable consistency in diagnosis.29
xvi The CMS sepsis quality measure uses the diagnosis criteria tool 
Sepsis-1, which was established in 1991. Sepsis-3 was proposed as 
an alternate definition in 2016, but not adopted as part of a CMS 
quality measure. Sepsis-3 has been adopted by the Surviving Sepsis 
campaign. See: https://acphospitalist.org/archives/2017/04/coding-sur-
viving-sepsis-campaign.htm
Notes: Septicemia is 3M APR™DRG 720. Selection of conditions based on literature and clinical input and confirmed 
by examining secondary diagnosis codes in stays with septicemia DRG. Payment is the average payment for that DRG 
based on HPC’s analysis of claims in the Massachusetts All-Payer Claims Database v6.0 for 2016.
Sources: HPC analysis of Center for Health Information and Analysis Hospital Inpatient Discharge Database, 
FY2010-FY2018 and All-Payer Claims Database v6.0; 3M APR™DRG classification system v26.0
Exhibit 3�1�6 Volume of inpatient stays for septicemia and select substitutable conditions 
for all payers, 2010 – 2018
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INCREASES IN INPATIENT ACUITY BY 
PAYER TYPE
The HPC examined acuity trends by market sector to further 
understand the causes and implications of increasing patient 
acuity. Exhibit 3.1.7 illustrates the changes in recorded patient 
acuity as well as length of stay and intensive care days sep-
arately for Medicare, MassHealth, and commercial patients. 
Acuity increased 10.9 percent for commercial patients (APR-
DRG), 7.9 percent for Medicare patients, and 18.4 percent for 
MassHealth patients. While patient length of stay and intensive 
care days did not increase for commercial or Medicare patients, 
both increased for MassHealth patients (though much less 
than did acuity), suggesting there was some worsening in the 
underlying health of MassHealth patients.
IMPLICATIONS OF INCREASING CODED 
PATIENT ACUITY
It is impossible to fully account for the underlying causes of 
the increase in recorded patient acuity, although changes in 
coding practices likely have played a large role.xvii The HPC 
explored additional alternative explanations such as shifts of 
less acute patients to observation status or outpatient settings 
and changes in technology that may have allowed treatment of 
xvii A number of hospitals have cited increases in documentation as a key 
factor in increasing revenue and margins. For example, see: https://
www.bizjournals.com/boston/news/2019/12/06/partners-reports-stel-
lar-financial-results-as-it.html.
sicker patients without increasing length of stay, and did not 
find evidence for these or other explanations.xviii To the extent 
that increases in recorded patient acuity are due to coding 
practices and not underlying health status changes, there are 
several implications that follow.
First and foremost, higher acuity directly translates to higher 
spending. For example, the reported acuity of Medicare patients 
in Massachusetts increased by 7.9 percent from 2013 to 2018 
(accompanied by a small decrease in length of stay and an 
18.2 percent decrease in intensive care utilization). Massachusetts 
inpatient spending for Medicare beneficiaries exceeded $5 billion 
in 2018; if patient acuity had remained at 2013 levels, spending 
would have been roughly $358 million lower in 2018 alone.xix
In MassHealth, the cost implications are less clear, partly 
because the agency changed inpatient payment systems in the 
middle of this period,xx and partly because MassHealth patients 
experienced an increase in length of stay and intensive care 
xviii As a sensitivity analysis, the HPC examined acuity trends in stays 
excluding potential candidate DRGs that could be treated in either 
inpatient or outpatient settings such as scheduled surgeries with length 
of stay of three days or less. The effect of removing these conditions 
resulted in a negligible change in acuity trend (less than 1 percent).
xix There could be a small offset to this spending increase in the form of 
reduced shared savings payouts to Medicare ACOs (due to higher 
per-beneficiary spending, which would reduce bonus payments). These 
would be very minor – total shared savings payouts by Medicare were 
approximately $1 million per ACO in 2018 and there were fewer than 
10 ACOs operating in Massachusetts in 2018.
xx MassHealth implemented its current DRG payment system in 2015. 
The agency further updated its weights in the middle of 2018. 
Notes: Both 3M APR™DRG v30.0 and MS-DRG acuity 
changes are shown for commercial payers because 
some payers use MS-DRG weights for their commer-
cial payments, although APR-DRG weights are more 
commonly used.
Sources: HPC analysis of Center for Health Infor-
mation and Analysis Hospital Inpatient Discharge 
Database, FY2013-FY2018; MS-DRG classification 
system updated annually, 3M APR™DRG classifi-
cation system v30.0 using 3M APRTMDRG weights 
for commercial and MassHealth v30.0 weights for 
MassHealth
Exhibit 3�1�7 Changes in acuity, length of stay, and intensive care days by payer, 2013 – 2018
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suggesting a true increase in acuity.xxi Thus, the HPC did not 
estimate a cost implication of increasing patient acuity among 
MassHealth patients.
Cost implications in the commercial sector are also difficult to 
estimate but are likely significant. Like Medicare patients, there 
was no observed increase in length of stay or intensive care 
use among commercial patients. However, some payers may 
have contract features with hospitals and providers whereby 
acuity increases are offset with payment reductions elsewhere. 
In addition, a few payers updated the weights they apply to a 
DRG/severity level in the middle of our period (see Sidebar: 
DRG Systems, DRG Weights, and Prices). These updates tend 
to offset somewhat the impact of coding the same patients into 
higher-severity DRGs and higher-severity levels. Nevertheless, 
based on data from CHIA regarding what DRG systems the 
commercial payers in Massachusetts have used for which years, 
we estimate a substantial implied commercial spending increase 
due to increased inpatient acuity of $280 million in 2018 alone.xxii
Second, as noted earlier, increases in patient acuity and risk 
scores that are not related to true changes in patient health 
status obscure performance measures that are health-status-ad-
justed. A recent study of reported mortality rates of veterans 
with pneumonia or heart failure found those rates appeared to 
improve much more than they actually did due to changes in 
coding practices, which led to an over-adjustment for health 
status in the mortality measure.30 As another example critical 
to Massachusetts, the performance improvement plan (PIP) 
provision in Chapter 224 as currently implemented calls for 
providers or payers to be referred to the HPC for potential 
improvement plans if their health-status-adjusted spending 
growth exceeds the benchmark (currently 3.1 percent). If 
an entity increases its risk score through coding efforts by 
2.2 percent (the average annual risk score growth between 
2013 and 2018), for example, it can avoid referral even with 
actual spending growth among its patient population of 
xxi Although behavioral health DRGs were removed from this analy-
sis, the increase in markers of acuity may include a slight effect of 
increased secondary diagnoses related to opioid use.
xxii This estimate is based on the following assumptions: we assume that 
60 percent of commercial inpatient stays were covered by payers 
that used the same APR-DRG weights in 2013 and 2018 and paid 
hospitals proportionally according to those updates, and that another 
15 percent of stays were covered by payers using the MS-DRG system 
which is automatically updated annually. We also assume no financial 
impact of increasing acuity for 25 percent of commercial inpatient 
stays (see Technical Appendix). 
xxiii Hospital volume increased among MassHealth patients, though much 
of this increase was due to an increase in opioid-related admissions.
5 percent, because risk-adjusted spending would be approx-
imately 2.8 percent.
SECTION 3�2: CHANGES IN COMMERCIAL 
INPATIENT VOLUME
The other key inpatient trend noted in the introduction to 
this chapter is a decline in total inpatient stays. Unlike patient 
acuity changes, which have occurred for all payers, declin-
ing volume has been a phenomenon mainly observed among 
commercially-insured patients (see Chartpack), which are the 
focus of the remainder of this chapter.xxiii Increasing hospital 
inpatient spending (due to both rising patient acuity and rising 
prices) combined with flat or declining commercial volume 
has resulted in rapidly increasing spending per hospital stay 
(see Exhibit 3.2.1). Indeed, hospital spending for commercial 
hospital stays grew 5.2 percent per year from 2013 to 2018, 
from approximately $14,500 to $18,700.
The decline in inpatient admissions may reflect a true change 
in population health needs, changes in clinical practice, or 
shifts to other sites of care. Trends in volume have important 
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Exhibit 3�2�1 Cumulative change in commercial inpatient hospital 
volume and commercial inpatient hospital spending, 2013 – 2018
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implications for hospital capacity and financing, and for overall 
spending in the Commonwealth. The HPC examined the trend 
in inpatient stays to understand the drivers behind the decline.
DECLINE IN INPATIENT ADMISSIONS BY 
TYPE OF ADMISSION
The HPC divided all admissions into four categories: behavioral 
health-related (BH), maternity, admissions from the emergency 
department (ED), and scheduled (see Technical Appendix). BH 
admissions include all stays where the primary diagnosis was 
for a mental health or substance use disorder. Maternity stays 
are those directly related to childbirth, dilation and curettage 
surgeries, and conditions arising in the ante- and post-partum 
periods. Admissions from the emergency department (ED) were 
any stays that originated in an emergency department. The 
remaining admissions were labeled as scheduled. These are 
typically admissions where a provider has requested a bed to be 
reserved for the patient for surgery or other medical treatment.
From 2013 to 2018, the largest declines were for scheduled 
admissions and for maternity admissions (19.4 percent and 
13.1 percent, respectively; see Exhibit 3.2.2). These two cate-
gories accounted for nearly 90 percent of the overall decline 
in commercial inpatient volume from 2014 to 2018.xxiv Admis-
sions from the ED and BH-related stays were relatively flat 
during this period, accounting for only 12 percent of the 
decline in volume.xxv
DECLINE IN MATERNITY-RELATED  
ADMISSIONS
The drop in maternity-related admissions appears to be directly 
related to a change in population characteristics, namely a 
drop in birth rates. From 2011 to 2016, the most recent years 
available, Massachusetts Department of Public Health (DPH) 
vital records show a 3.9 percent decline in the rate of births to 
Massachusetts residents (from 54.1 to 52.0 per 1000 women 
aged 15-44), mirroring national trends.31, 32 During this same 
time period, the number of maternity-related commercial-
ly-insured inpatient stays in Massachusetts fell by a similar 
4.5 percent (similar to data in Exhibit 3.2.2, but over slightly 
different years to match the DPH data).
xxiv Admissions from the ED dropped between 2013 and 2014 according 
to the Hospital Discharge Data. Because this one-year change appears 
anomalous (and may be due to changes in data definitions), the remain-
der of the chapter focuses primarily on the 2014 to 2018 period.
xxv The Center for Health Information and Analysis HIDD only captures 
admissions from acute-care hospitals. Behavioral health hospitals are 
not included in this data set. For more information see Technical 
Appendix: Data Sources.
Notes: Maternity includes all dis-
charges with a maternity-related 
DRG. ED admissions include 
all discharges with an ED flag 
or ED-specific revenue code. 
Behavioral health (BH) discharges 
include all discharges with a BH 
diagnosis as the primary diagno-
sis. Scheduled includes remaining 
discharges. All figures reflect 
rounding.
Sources: HPC analysis of Center 
for Health Information and Analysis 
Hospital Inpatient Discharge Data-
base, FY2013 – FY2018
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Exhibit 3�2�2 Inpatient admissions per 1,000 commercial members by type of 
admission and contribution to volume decline, FY 2013 – FY 2018
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Not all Massachusetts hospitals have experienced this decline 
in births equally (see Exhibit 3.2.3). Community high public 
payer hospitals (HPP) experienced the largest decline among 
hospital types, with a 19.9 percent decline in the volume of 
births from 2014 to 2018. During this same four-year period, 
academic medical centers (AMC) and other teaching hospitals 
experienced a much smaller decline (7.6 percent and 2.5 percent, 
respectively). This differential loss of maternity-related admis-
sions has resulted in a decline in the proportion of overall 
births occurring in all community hospitals–from a high of 
50.1 percent in 2016 to 47.9 percent in 2018. Maternity-re-
lated admissions are an essential source of revenue for many 
community hospitals, but the trend in births shifting away 
from community hospitals coupled with a declining birth rate 
overall is likely related to some maternity services closing or 
proposing to be closed in the state.33 Lack of local maternity 
beds can be problematic from the perspective of women not 
having a choice to deliver closer to home, while more maternity 
stays occurring in more expensive settings is problematic from 
a cost containment perspective.
DECLINE IN SCHEDULED INPATIENT 
ADMISSIONS AND SHIFTS TO 
OUTPATIENT SETTINGS
As with maternity admissions, the decline in scheduled inpatient 
volume was much greater among community HPP hospitals; 
volume for these hospitals declined 32.3 percent, compared 
with 15.6 percent for AMCs. Though some of the declining 
volume could be related to changes in underlying population 
health needs and changes in clinical practice (see Sidebar: 
Appendectomy),34, 35, 36 shifts in care from inpatient to outpatient 
settings also likely account for some portion of the decline in 
the number of scheduled inpatient admissions observed in 
Exhibit 3.2.2.xxvi 
xxvi Between 2014 and 2018 the number of scheduled hip and knee proce-
dures increased markedly, by roughly 1,000 commercial admissions. 
If this had not happened, the decline in scheduled admissions would 
have been larger. 
Notes: Maternity includes all discharge with Major Diagnostic Category 14 
(MDC 14 and 15). All figures reflect rounding.
Sources: HPC analysis of Center for Health Information and Analysis Hospital 
Inpatient Discharge Database, FY2014 – FY2018
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Exhibit 3�2�3 Maternity discharges by hospital cohort, 2014 – 2018
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SIDEBAR: APPENDECTOMY
One example of a clinical practice change leading to a 
decline in inpatient admissions is appendectomy. Appen-
dectomy refers to the removal of an inflamed appendix 
to prevent rupture and further spread of infection. The 
procedure is relatively common, with about 300,000 per-
formed in the U.S. annually.37 Yet the number of commercial 
inpatient stays in which appendectomies were performed 
in Massachusetts declined from 3,808 in 2011 to 1,579 in 
2014 to 1,094 in 2018 (most inpatient stays where appen-
dectomies are performed result from an ED visit, though 
some are also scheduled). Clinical practice for treating an 
inflamed appendix has been changing in recent years. First, 
clinicians have increased use of radiology to confirm the 
need for an appendectomy, preventing some unnecessary 
pre-operative procedures. Also, researchers have discov-
ered non-surgical methods to treat an inflamed appendix, 
such as the increasing use of antibiotics. In a 2016 study, 
antibiotics (e.g. Ertapenem) were found to be just as effec-
tive as surgery.38 Analysis of the APCD confirmed that the 
decline in inpatient appendectomy procedures was not due 
to a shift to outpatient settings; the share of appendecto-
mies taking place in inpatient settings remained unchanged 
at approximately 37 percent between 2015 and 2017.
When we examine the individual APR-DRGs responsible for 
the largest decline in the volume of commercial scheduled 
admissions between 2014 and 2018, those that stand out 
are admissions involving female oncology and reproductive 
system procedures (e.g., mastectomy, hysterectomy, ovarian 
cyst removal), musculoskeletal procedures such as disc removal 
and spinal fusion, and surgical bowel procedures. Many of 
these have been examined previously. In both the 2015 and 
2017 Cost Trends Reports, the HPC highlighted trends in a 
particular set of “cross-over” procedures (mostly surgeries) that 
were commonly performed in either inpatient settings or on an 
outpatient basis.39, 40 These cases demonstrated a gradual shift 
from inpatient to outpatient settings, consistent with overall 
U.S. trends. Nationally, the share of all hospital-based surgeries 
performed in inpatient settings dropped from 36.8 percent in 
2008 to 33.0 percent in 2016.41
Here, we revisit these cross-over procedures as well as addi-
tional surgical procedures with the potential to shift settings 
(see Exhibit 3.2.4). From FY2013 to FY2018, these 11 surgical 
case studies, defined by major procedure performed rather 
than by DRG (so they can be identified in both inpatient and 
outpatient settings), collectively accounted for 21.3 percent 
of the overall decline in commercial inpatient admissions and 
39.1 percent of scheduled admissions.
Description 2013 2018 Difference Percent change
Hysterectomy, abdominal and vaginal 2,748 1,035 1,713 -62%
Appendectomy 2,174 1,094 1,080 -50%
Cholecystectomy and common duct exploration 2,252 1,539 713 -32%
Percutaneous transluminal coronary angioplasty 2,495 1,926 569 -23%
Other vascular catheterization, not heart 2,310 1,795 515 -22%
Other hernia repair 897 391 506 -56%
Thyroidectomy, partial or complete 636 171 465 -73%
Spinal fusion 2,885 2,628 257 -9%
Diagnostic cardiac catheterization, coronary arteriography 1,850 1,658 192 -10%
Mastectomy 666 506 160 -24%
Inguinal and femoral hernia repair 154 93 61 -40%
Notes: Procedures are identified and grouped according to the Clinical Classification System (see Technical Appendix for more detail). All figures reflect 
rounding. Each procedure identified in the table was the main procedure performed during an inpatient admission.
Sources: HPC analysis of Center for Health Information and Analysis Hospital Inpatient Discharge Database, FY2013 – FY2018
Exhibit 3�2�4 Number of selected commercial inpatient discharges in Massachusetts, according to major surgical procedure, 2013 and 2018
HEALTH POLICY COMMISSION2019 COST TRENDS REPORT - 32 -
In order to determine whether these declines represent further 
shifts to outpatient settings, the HPC selected three cases from 
Exhibit 3.2.4 for further study (hysterectomy, spinal fusion, 
and mastectomy) among commercial patients in the APCD, 
where these surgeries can be identified in both inpatient and 
outpatient settings.xxvii Exhibit 3.2.5 shows that for these three 
case studies, and for all cases identified in Exhibit 3.2.4, there 
was indeed a significant shift from inpatient to outpatient set-
tings. For example, of all abdominal and vaginal hysterectomies 
performed in 2015, 43 percent took place in inpatient settings 
while 57 percent took place in outpatient settings. Just two 
years later, these proportions had shifted to 32 percent and 
68 percent, respectively.
xxvii The data in Exhibit 3.2.4 represent all payers and originate from 
inpatient discharge data, which does not include surgeries performed 
in outpatient settings. 
As noted earlier, declining volume in scheduled inpatient pro-
cedures has not been uniform across types of hospitals, with a 
loss of volume being experienced in particular by community 
HPP hospitals. With respect to cases that may be shifting 
from inpatient to outpatient settings, if those hospitals were 
retaining that lost volume in their outpatient facilities, then 
the financial impact on their systems and on the market as 
a whole might be relatively minor. However, this does not 
appear to be the case.
20172015201720152017201520172015
47.1%
52.9%
45.3%
54.7%
91.2%
8.8%
86.0%
14.0%
60.0%
40.0%
54.3%
45.7%
42.6%
57.4%
32.2%
67.8%
ALL CASE STUDY PROCEDURES SPINAL FUSION MASTECTOMY
HYSTERECTOMY, 
ABDOMINAL AND VAGINAL
Outpatient Inpatient
100%
0%
100%
0%
Notes: Procedures are identified and grouped according to the Clinical Classification System (see Technical Appendix). All figures 
reflect rounding. Each procedure identified in the figure was the main procedure performed during an inpatient admission.
Sources: HPC analysis of Center for Health Information and Analysis All-Payer Claims Database v7.0
Exhibit 3�2�5 Percent of surgeries taking place in inpatient and outpatient settings for select case studies, 2015 – 2017
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Exhibit 3.2.6 shows the change in the inpatient and outpa-
tient volume by hospital system for hysterectomy. The figure 
also shows the net change in volume, combining changes in 
inpatient and outpatient volume; hospital systems are sorted 
top to bottom by the highest net growth in volume. While 
most systems experienced declines in inpatient volume for 
these procedures, some were better able to make up for the 
loss with increases in their outpatient settings. Overall, the 
systems losing net volume tended to include more lower-priced 
community hospitals while those gaining were more likely to 
include higher-priced AMCs.
These cross-provider system shifts in outpatient care have 
implications for changes in overall spending which are explored 
further in the next chapter.
xxviii In November 2019 Partners HealthCare announced it was changing 
its system name to Mass General Brigham. Since this report uses 
2017 data that does not include all the hospitals within the Mass 
General Brigham hospital system, the report uses the Partners name. 
All others
Steward
Southcoast 
Wellforce
Cape Cod 
Baystate Health
South Shore
Lahey 
UMass
Beth Israel
Partners 
Net change in volume Outpatient change in volume Inpatient change in volume
G
A
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D
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O
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L
O
S
T
 V
O
L
U
M
E
68
48
50
110
-42
-2
8
3
5
17
-16
-6
1
-3
-4
-9
6
-14
-23
-13
-3
-10
-15
-27
12
-10
10
13
7
1
-60
20
-80
Notes: The analysis only includes codes for hysterectomies that might reasonably be performed in an outpatient setting. 
These cases excluded complicated hysterectomy, maternity-related hysterectomy, and hysterectomies that involved 
cervical, uterine, or ovarian cancer. Hospital systems as shown include ownership as of 2017. Outpatient surgeries taking 
place at off-campus hospital sites for these hospitals are included. Partnersxxviii includes: Massachusetts General, Brigham 
& Women’s, Brigham & Women’s Faulkner, Cooley Dickinson, Martha’s Vineyard, Nantucket Cottage, Newton-Wellesley, 
and North Shore Medical Center. Beth Israel includes: Beth Israel Deaconess Medical Center, BID-Milton, BID-Needham, 
and BID-Plymouth. UMass Memorial includes: UMass Memorial Medical Center, Clinton, HealthAlliance, and Marlborough. 
Lahey includes: Lahey Hospital & Medical Center, Northeast, and Winchester. Baystate Health includes: Baystate Medical 
Center, Baystate Franklin Medical Center, Baystate Noble, and Baystate Wing. Cape Cod includes: Cape Cod and Falmouth. 
Wellforce includes: Tufts Medical Center, Lowell General, and Hallmark. Steward includes: St. Elizabeth’s Medical Center, 
Carney, Good Samaritan Medical Center, Holy Family, Morton, Nashoba Valley Medical Center, Norwood, and Saint Anne’s. 
South Shore and Southcoast were independent in 2017.
Sources: HPC analysis of Center for Health Information and Analysis All-Payer Claims Database v7.0
Exhibit 3�2�6 Change in volume of hysterectomy procedures by hospital system, 2015 – 2017
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$CHAPTER 4:  
HOSPITAL OUTPATIENT 
SPENDING GROWTH
Shifting of hysterectomy from inpatient to outpatient 
settings would save money, yet savings are eroded by price 
increases in both settings and a shifting of surgery cases 
from low-cost hospitals to high-cost hospitals. 
Hospital outpatient spending accounts for 60 percent of 
hospital spending for commercially-insured residents, with 
outpatient surgery accounting for more than a third of total 
hospital outpatient spending. Spending in this subcategory 
grew 11 percent from 2015 to 2017.
Among outpatient surgery episodes, spending on major 
surgery grew 9.5 percent from 2015 to 2017, driven by a 
10.2 percent increase in hospital payments per episode. 
Among the six highest-volume hospitals, payments per 
major outpatient surgery episode were nearly twice as 
high at Massachusetts General Hospital and Brigham and 
Women’s Hospital as the lowest-paid high-volume hospital.
2x
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CHAPTER 4:  
HOSPITAL OUTPATIENT 
SPENDING GROWTH
In 2018, hospital outpatient spending accounted for nearly 
20 percent of all health care spending in Massachusetts.i In 
the commercial sector, hospital outpatient spending is even 
more prominent, accounting for 25 percent of all spending 
and exceeding hospital inpatient spending (17 percent of all 
spending).ii Hospital outpatient spending has also been grow-
ing relatively quickly, particularly in the commercial market. 
Spending increased $700 million (from $5.1 billion to $5.8 
billion) between 2015 and 2018 and accounted for 31 percent 
of all commercial spending growth over that time period. As 
noted in Chapter 3, some of this growth can be attributed to 
moving certain procedures from an inpatient setting to an out-
patient setting, although these shifts cannot explain the majority 
of the growth.iii This chapter focuses on drivers of commercial 
i When CHIA reports total medical expenditures, hospital outpatient 
(and inpatient) spending only includes the facility component (the 
portion paid directly to the hospital) of a patient’s encounter, not any 
of the professional spending. 
ii Community hospitals, on average, derive roughly two-thirds of their 
commercial revenue from outpatient services. 
hospital outpatient spending and growth. Hospital outpatient 
includes services that are performed either within the hospital’s 
main campus or at an off-campus satellite hospital site (see 
Exhibit 4.1 and Sidebar: Hospital Outpatient Departments).
iii For example, the number of commercial inpatient stays declined 
by 13,000 between 2015 and 2018, including a decline of 6,500 
scheduled admissions. Even if most of those admissions were treated 
in outpatient settings, they would account for only a small fraction 
of outpatient spending growth between 2015 and 2018. 
iv All of the surgeries studied had to have a billing NPI listed on the 
facility bill for an in-state acute care hospital in Massachusetts.
INPATIENT OUTPATIENT
OUTPATIENT
Hospital main campus Hospital o-campus satellite
Exhibit 4�1 Hospital outpatient departments
HOSPITAL OUTPATIENT DEPARTMENTS
The focus of this chapter is the spending and services that 
take place in the hospital outpatient departments of acute 
care hospitals in Massachusetts (a very small fraction – 
less than 5 percent – of surgeries included in some of the 
topline figures occur in ambulatory surgery centers, urgent 
care centers, or other settings that have a facility compo-
nent). Hospital outpatient departments provide a range of 
medical services including regular doctor visits, emergency 
department visits, surgeries, imaging, and labs. These 
services could be performed either within the hospital’s 
main campus or at an off-campus satellite hospital site, 
which could be far from the hospital. For this work the HPC 
does not distinguish between these two types of settings 
if both were billed by the same acute care facility.iv Most 
reporting of hospital outpatient spending only includes 
payments that go directly to the hospital and excludes 
payments to physicians and other professionals involved in 
the encounter. In some instances in this chapter, as noted, 
the HPC includes these professional payments as well as 
those received by the hospital (see Technical Appendix).
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In order to understand better what services have driven growth 
in commercial hospital outpatient spending, the HPC first 
grouped all claims in this category in the All-Payer Claims Data-
base (APCD) into seven service sub-categories (see Technical 
Appendix).v Surgery comprised the largest share of commercial 
outpatient spending in 2017 at 34 percent (see Exhibit 4.2). 
Other major components of commercial hospital outpatient 
spending include radiology (17 percent), emergency room 
spending (12 percent), and administered drugs (13 percent). 
Of these spending categories, administered drugs grew fastest 
v Data include claims from members insured by Blue Cross Blue Shield 
of Massachusetts, Tufts Health Plan, Harvard Pilgrim Health Care, 
Neighborhood Health Plan (now AllWays Health Partners), or Anthem 
BCBS. These payers represent roughly 71 percent of the commercial 
market in Massachusetts. Due to the Gobeille v. Liberty Mutual Insur-
ance ruling (2016), most claims from self-insured employers are no 
longer included in the APCD and thus, the APCD’s representation of 
the commercial market is less than it would otherwise be. Since total 
members represented by these payers fluctuated between 2015 and 
2017, all results are reported on a per-member or per-encounter basis.
(44 percent between 2015 and 2017). Growth in outpatient 
surgery accounted for over one-third of hospital outpatient 
spending growth during the period. Due to its large contribu-
tion to growth and total spending, as well as its relationship to 
trends occurring throughout the health care system (including 
shifts from inpatient settings), the remainder of this chapter 
focuses on outpatient surgery.vi
PATTERNS IN SPENDING, PAYMENTS, 
AND UTILIZATION FOR MAJOR AND 
MINOR SURGERIES
To analyze trends in outpatient surgery, the HPC created 
outpatient surgery encounters from the APCD and subdi-
vided these encounters into “major,” “minor,” and “other” 
based on the main surgical procedure taking place in each 
vi Nevertheless, the other categories of spending growth are important 
and may indicate inefficient use of resources. They may be explored 
in greater depth in future reports.
Notes: Percent in grey above bars represents percent growth in spending between 2015 and 2017. 
Methodology based on Health Care Cost Institute’s (HCCI) 2017 Health Care Cost and Utilization Report.
Sources: HPC analysis of Center for Health Information and Analysis All-Payer Claims Database v7.0
2015
2017
$0
$100
$200
$300
$400
$500
OtherObservationLab/pathologyEmergency
room
Administered
drug
RadiologyOP surgery 
34.1%
16
.6
%
1
2
.9
%
1
2
.1
%
9
.3
%
1
3
.0
%1.9%
10.7%
12.4%
43.8%
12.3%
10.5%
-3.2%
-2.7%
HOSPITAL OUTPATIENT SPENDING IN 2017
2015
2017
$0
$100
$200
$300
$400
$500
OtherObservationLab/pathologyEmergency
room
Administered
drug
RadiologyOP surgery 
34.1%
16
.6
%
1
2
.9
%
1
2
.1
%
9
.3
%
1
3
.0
%1.9%
10.7%
12.4%
43.8%
12.3%
10.5%
-3.2%
-2.7%
HOSPITAL OUTPATIENT SPENDING IN 2017
2015
2017
$0
$100
$200
$300
$400
$500
OtherObservationLab/pathologyEmergency
room
Administered
drug
RadiologyOP surgery 
34.1%
16
.6
%
1
2
.9
%
1
2
.1
%
9
.3
%
1
3
.0
%1.9%
10.7%
12.4%
43.8%
12.3%
10.5%
-3.2%
-2.7%
HOSPITAL OUTPATIENT SPENDING IN 2017
Exhibit 4�2 Hospital outpatient spending per member-year by HCCI outpatient service category, 2015 – 2017
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encounter.vii, 1 For purposes of this study, major outpatient 
surgeries included invasive therapeutic surgeries that typically 
involve an operating room, anesthesia, and incisions or other 
manipulation that penetrates the skin (e.g., knee replace-
ments, hysterectomy). Minor outpatient surgeries are defined 
as therapeutic or diagnostic surgeries that are not classified 
as major outpatient surgeries, but may include percutaneous 
and endoscopic procedures (e.g., colonoscopies, biopsies). 
“Other” encounters included various minor procedures such as 
an intrauterine device (IUD) placement and ear wax removal. 
Under this classification system, major outpatient surgical 
episodes comprised just under half of outpatient surgery spend-
ing (49 percent), minor episodes accounted for 27 percent of 
spending, and “other” represented 24 percent.
Surgery payments included a hospital component that reflects 
fees for overhead (such as operating room use, equipment, 
and nursing staff), as well as a professional component that 
vii Each outpatient surgery encounter was anchored with a facility claim 
indicating surgery, and then included all claims (facility and profes-
sional) for the same member occurring at same site on the same day 
as the anchoring facility claim. Pre-operative testing that took place 
outside this window as well as any follow-up care related to the surgery 
was not included in the surgery encounter for this analysis. For more 
details on the HPC’s outpatient surgery encounter methodology, see 
Technical Appendix.
reflects fees for surgeon and anesthesiology services. Most 
spending for hospital outpatient surgical encounters was for 
the hospital component (71 percent, compared to 29 percent 
for professional fees).
Total spending for major outpatient surgery episodes grew 
9.5 percent from 2015 to 2017 (see Exhibit 4.3). This growth was 
driven primarily by growth in payment per episode (8.6 percent, 
from $8,246 to $8,955), which in turn was driven more by 
growth in payment for the hospital component (10.2 percent) 
than growth in payment for the professional component 
(4.8 percent).viii Only a small portion of spending growth was 
driven by an increase in the number of major outpatient surgeries, 
which grew just under 1 percent over this period.
Minor surgeries showed the opposite dynamic. Total spending 
increased 6.8 percent between 2015 and 2017 but was pri-
marily driven by an increase in volume (5.6 percent). Growth 
in payment per surgery was minimal ($3,157 in 2015 and 
$3,192 in 2017).ix
viii Increasing complexity is an unlikely explanation for the rising pay-
ments; the average relative value unit (RVU) of the main procedure in 
the encounter, a measure of complexity, only increased by 1 percent 
over the period.
ix As with major surgeries, the complexity (RVUs) of an average proce-
dure remained virtually unchanged (-0.2 percent).
Professional
payment
Facility
payment
Total
payment
Total
volume
Total
spending 
PER ENCOUNTERPER MEMBER
9.5%
0.8%
8.6%
10.2%
4.8%
Professional
payment
Facility
payment
Total
payment
Total
volume
Total
spending 
PER ENCOUNTERPER MEMBER
6.8%
5.6%
1.1%
0.8%
2.0%
MAJOR SURGERY MINOR SURGERY
Notes: Total spending and payments include all facility and professional claim lines associated with an encounter. N is 
total number of distinct surgery encounters with at least one surgery facility fee. Results adjusted for member months.
Sources: HPC analysis of Center for Health Information and Analysis All-Payer Claims Database v7.0; AHRQ surgery flags
Exhibit 4�3 Growth in spending, volume, and payments for major and minor outpatient surgeries, 2015 – 2017
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MAJOR OUTPATIENT SURGERIES
A more in-depth examination of the top subcategories of major 
outpatient surgeries reveals a number of additional important 
trends. Exhibit 4.4 displays the top 12 types of major out-
patient surgery in terms of total spending, ordered from top 
to bottom by volume. Together, these procedure categories 
represent 39 percent of volume and 34 percent of spending 
on major outpatient surgeries in 2017.
Consistent with Exhibit 4.3, payments rose for all of the top 
surgical categories, typically between 5 percent and 10 percent 
from 2015 to 2017. For most categories, relative value units 
(RVUs) did not change appreciably, suggesting that the payment 
increases were not capturing increases in complexity or medical 
need.2 One exception was “other hernia repair,” for which the 
average RVU for the encounter increased by 6 percent. This 
category was also noted in the previous chapter (Exhibit 3.2.4) 
as a procedure with declining inpatient volume. It is possible 
that, as more hernia repair surgeries are done in outpatient 
rather than inpatient settings, the cases that shift from inpatient 
settings are somewhat more complex than those that had been 
performed in outpatient settings previously. If so, this could 
potentially explain some of the increase in complexity across 
all hospital outpatient “other hernia repairs.”
Changes in volume were more mixed. Several procedures 
declined in volume over the study period, including some 
knee and joint procedures, lumpectomy, and decompression 
of peripheral nerve. Reductions in volume could be due to 
a shift from hospital outpatient to physician office settings 
and/or changes in technology and clinical practice. Other 
procedures, such as myringotomy (placement of ear tubes), 
tonsillectomy/adenoidectomy, and hysterecomy, saw large 
increases in volume. See Sidebar: Growth in Children’s Surgery: 
Myringotomy and Tonsillectomy/Adenoidectomy.
Hysterectomy was highlighted in Chapter 3 as an example of 
a procedure that has shifted from inpatient to outpatient set-
tings, and Exhibit 4.4 is consistent with that finding, showing 
MAJOR SURGERIES 2017 PERCENT CHANGE 2015 TO 2017
  N Payment per surgery
N per 
member
Payment per 
surgery
Complexity 
(RVU)
Excision of the knee cartilage 3065 $ 6,171 -14% 4% 1%
Tonsillectomy and/or adenoidectomy 2498 $ 6,456 8% 7% 1%
Lumpectomy, quadrantectomy of breast 2354 $ 9,212 -8% 12% 3%
Inguinal and femoral hernia repair 2182 $ 8,765 -3% 9% -1%
Decompression of peripheral nerve 1926 $ 4,818 -8% 6% 1%
Lens and cataract procedures 1922 $ 4,804 4% 8% 0%
Other hernia repair 1755 $ 8,745 4% 6% 6%
Myringotomy 1695 $ 4,964 11% 10% 0%
Cholecystectomy and common duct exploration 1683 $ 8,542 -4% 4% 0%
Hysterectomy, abdominal and vaginal 1353 $ 13,737 29% 8% 2%
Plastic procedures on nose 1211 $ 11,668 -2% 12% 3%
Bunionectomy or repair of toe deformities 1124 $ 7,748 -7% 7% 0%
Notes: Categories of major outpatient surgeries shown in table are among the top 15 in overall spending, have at least 1,000 surgeries in 2017, and represent 
at least 1 percent of total major outpatient surgery spending. Several categories in the top 15 were removed due to non-specific collections of surgeries and 
heterogeneity within the category. These included: “other intraocular procedures”, “other OR procedures on joints,” “other OR procedures on skin,” and “other 
therapeutic procedures on musculoskeletal system.” Changes from 2015 to 2017 are reported on a per-member-month basis.
Sources: HPC analysis of Center for Health Information and Analysis All-Payer Claims Database v7.0; AHRQ surgery flags
Exhibit 4�4 Change in volume, payment, and severity for twelve major outpatient surgery categories, 2015 – 2017
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a 29 percent increase in outpatient volume 
for the procedure from 2015 to 2017. The 
average hospital outpatient payment for hys-
terectomy was, on average, 28 percent lower 
than a similar inpatient surgery in 2017, sug-
gesting the shift should be cost-saving. Instead, 
there was a 9.5 percent increase in average 
payment for uncomplicated hysterectomies 
in both the inpatient and outpatient settings 
combined. When examined in more detail, 
this paradox appears to be explained by both 
price increases for a given procedure over the 
two years, and by a shift from hospitals with 
lower-priced inpatient surgeries to hospitals 
with higher-priced outpatient surgeries (see 
Exhibit 4.5).
For example, the average payment for an inpa-
tient hysterectomy at Steward Good Samaritan 
Medical Center in Brockton (the hospital that 
lost the most inpatient volume from 2015 to 
2017) in 2017 was $14,683, and the average 
payment for an outpatient hysterectomy was 
$10,852. At Brigham and Women’s Hospital 
(the hospital that gained the most outpatient 
volume over the period), the average inpatient 
payment was $25,767 and the average outpa-
tient payment was $20,144. For each of these 
hospitals, shifting a patient within the hospital 
from the inpatient setting to the outpatient 
setting would result in roughly 25 percent 
lower spending; however, shifting a hypothet-
ical patient from the inpatient setting at Good 
Samaritan to an outpatient setting affiliated 
with Brigham and Women’s Hospital would 
result in a spending increase of 37 percent 
(note: we are unable to observe actual patient 
shifts, that is, where a patient receiving an 
outpatient hysterectomy procedure at Brigham 
and Women’s Hospital in 2017 might have 
otherwise gone).x
Across the Commonwealth, the average inpa-
tient hysterectomy payment was $5,300 higher 
than the average outpatient hysterectomy 
x There are numerous factors that could explain 
such shifts, including patient choice, provider 
referrals, and hospital capacity.
Notes: The hospitals shown had the largest loss in inpatient hysterectomy volume (Good Samaritan) 
and the largest gain in outpatient hysterectomy volume (Brigham and Women’s Hospital).  These 
data do not imply that any specific patient chose Brigham and Women’s Hospital instead of Good 
Samaritan, but rather are an example to highlight the potential associated spending impact. Cases 
included in the figure exclude complicated hysterectomies as well as hysterectomies related to 
ovarian cancer or maternity admissions.
Sources: HPC analysis of Center for Health Information and Analysis All-Payer Claims Database v7.0
Exhibit 4�5 Average payment for inpatient and outpatient hysterectomy at 
selected hospitals
SIDEBAR: GROWTH IN CHILDREN’S SURGERY: 
MYRINGOTOMY AND TONSILLECTOMY/
ADENOIDECTOMY
Myringotomies (ear tube placement) and tonsillectomies/adenoidectomies 
(removal of the tonsils and/or adenoids) are major outpatient surgeries performed 
mostly in children age 16 or younger (94 percent and 69 percent of all myringot-
omies and tonsillectomies /adenoidectomies, respectively, are performed on this 
age group). Between 2015 and 2017, the number of these surgeries performed 
on children increased by 18.5 percent. Almost all are performed in hospital out-
patient departments or hospital-owned surgery centers, and in 2017, 65 percent 
of myringotomies and 63 percent of tonsillectomies/adenoidectomies were 
performed in just two hospitals: Boston Children’s Hospital and Mass. Eye and 
Ear. This finding is consistent with broad trends nationally in regard to low-risk, 
high-volume pediatric procedures and a general concentration of pediatric care 
into a small number of settings in Massachusetts.3, 4 While it is not unusual for 
children’s surgeries to concentrate into a small number of settings, it remains 
unclear why there is an additional overall volume increase in these surgeries. 
A review of the current clinical guidelines does not indicate a shift in practice; 
some guidelines suggest that these procedures should be occurring less often, 
in favor of more medical management.5 Further research is needed to understand 
what these trends suggest about utilization of these services in Massachusetts.
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payment.xi But as in the example shown in Exhibit 4.5, the 
predominant pattern of net inpatient to outpatient shifts for 
these procedures, as shown in Chapter 3, was not within 
hospitals, but from lower-cost to higher-cost hospitals which 
resulted in increased spending. Although overall spending 
impacts are more moderate than in Exhibit 4.5, the average 
payment for a hysterectomy at hospitals that lost volume from 
2015 to 2017 was $14,300, while the average payment for a 
hysterectomy at hospitals that gained volume was $15,100.xii
MINOR SURGERIES
As noted in Exhibit 4.3, spending increased for minor surgeries 
as well as major outpatient surgeries, but that spending increase 
was driven more by volume growth than payment growth 
overall. Exhibit 4.6 lists the top categories of minor surgeries 
by total spending, sorted by volume. In 2017, three minor sur-
gery categories accounted for about half of all minor surgery 
xi Average inpatient hysterectomy payment was calculated for DRGs 
that could potentially be shifted to outpatient settings. However, 
hysterectomies that remained in inpatient settings in 2017 might still 
be more complex on average than outpatient hysterectomies, so the 
difference between inpatient and outpatient payment may overstate 
the cost savings from an inpatient to outpatient shift.
xii These figures represent the average payment at hospitals that had 
hysterectomy volume gains or losses of 5 cases or more between 2015 
and 2017, weighted by their corresponding gain or loss. See Technical 
Appendix.
spending in hospital outpatient departments: colonoscopies 
with excision or biopsy (29.5 percent of spending), endoscopies 
with biopsy (15.4 percent), and breast biopsies (5.1 percent).xiii
The overall increase in volume and lack of a significant payment 
increase for minor surgeries as a group was primarily driven by 
the rise in volume and decrease in average payment for colo-
noscopies with biopsy. The number of colonoscopy procedures 
increased by 7.7 percent in hospital outpatient departments, 
while payments per procedure declined 5 percent between 2015 
and 2017. A significant number of these procedures occur in phy-
sician-owned ambulatory (non-hospital) settings (29 percent of 
all volume), and competition from these settings may be leading 
to a reduction in hospital prices for the procedure. Spending on 
the procedure is 36 percent lower when performed in physician 
office settings. While volume increased between 2015 and 2017 
in both settings, the increase was greater in physician office 
settings (19.5 percent) than in hospital settings (7.7 percent). 
The greater volume increase in physician office settings may be 
due to a lower price point in these settings.
Five of the other seven high-spend minor procedure catego-
ries in Exhibit 4.6 saw an increase in payment per procedure. 
Breast biopsies, lithotripsies, and dilation and curettage (D&C) 
xiii Further references to colonoscopy in this chapter use the shorthand 
“colonoscopy” but refer only to cases where a biopsy was performed, 
as opposed to a screening colonoscopy that does not include a biopsy.
Exhibit 4�6 Change in volume, payment, and severity for minor surgery categories taking place in hospital outpatient by spending, 2015 – 2017
MINOR SURGERIES 2017 PERCENT CHANGE 2015 TO 2017
  N Payment per surgery N per member Payment per surgery Complexity (RVU)
Colonoscopy and biopsy 31111 $ 2,873 8% -5% 0%
Upper gastrointestinal endoscopy, biopsy 15976 $ 2,907 3% 4% 1%
Breast biopsy 6251 $ 2,466 7% 12% 2%
Debridement of wound, infection or burn 4391 $ 710 12% -13% 1%
Excision of skin lesion 3526 $ 3,019 -7% 5% 9%
Suture of skin and subcutaneous tissue 1643 $ 1,490 19% -12% -6%
Abdominal paracentesis 1225 $ 1,942 34% 1% 0%
Extracorporeal lithotripsy, urinary 1046 $ 8,971 15% 13% 0%
Esophageal dilatation 1021 $ 3,386 19% 8% -1%
Dilatation and curettage (D&C) 1000 $ 4,898 4% 10% 0%
Notes: Categories of minor surgeries shown in the table had at least 1,000 surgeries and represented more than 1 percent of total spending for 
minor surgeries in 2017.
Sources: HPC analysis of Center for Health Information and Analysis All-Payer Claims Database v7.0; AHRQ surgery flags
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procedures had payment increases of at least 
10 percent. These procedures were rarely 
performed in physician offices (17 percent, 
5 percent, and 19 percent, respectively) and 
thus may face less price competition from 
those settings. Only excisions of skin lesions 
had a significant increase in RVUs, suggesting 
that the payment increase in that category 
might be related to increasing complexity of 
the procedures.
CONCENTRATION OF SURGERY 
VOLUME AND SPENDING 
ACROSS HOSPITAL SYSTEMS
Both major and minor hospital outpatient 
surgeries are highly concentrated in a few 
hospital systems, and this concentration con-
tinues to grow. In 2017, 28 percent of all 
major outpatient surgeries occurred at either 
Partners HealthCare or Beth Israel hospitals 
(see Exhibit 4.7). Since 2017, these systems 
have grown (Partners HealthCare acquired 
Mass. Eye and Ear in 2018 and Beth Israel 
merged with Lahey and several other hospitals 
in 2019). Based on their current affiliations, 
Partners HealthCare and Beth Israel-Lahey 
Health account for 52 percent of volume.xiv 
Because of higher payment levels per surgery, 
Partners HealthCare hospitals account for an 
even higher share of spending. Partners Health-
Care performed one in five major surgeries 
in 2017, but accounted for 27.2 percent of 
spending for these surgeries.
xiv In 2018, Partners HealthCare acquired Mass. Eye 
and Ear Infirmary (MEEI) and all of its subsidiaries. 
In 2019, Lahey Health System; Caregroup and its 
component parts (Beth Israel Deaconess Medical 
Center, New England Baptist Hospital, and Mount 
Auburn Hospital); Seacoast Regional Health Sys-
tems; and all of their corporate subsidiaries merged 
to form Beth Israel Lahey Health (BILH). BILH 
also acquired Beth Israel Deaconess Care Orga-
nization and established a contracting affiliation 
with Mount Auburn Cambridge Independent Prac-
tice Association. For more information on these 
transactions, please refer to the HPC’s final Cost 
and Market Impact Review reports: MEEI (https://
www.mass.gov/doc/final-cmir-report-phs-mee-0/
download); BILH (https://www.mass.gov/doc/
final-cmir-report-beth-israel-lahey-health/download).
Exhibit 4�7 Share of spending and volume of major outpatient surgeries by hospital 
system, 2017; including both prior and current hospital system affiliations
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Brigham and Women’s, Brigham and Women’s Faulkner, Cooley Dickinson, Martha’s Vineyard, Nan-
tucket Cottage, Newton-Wellesley, and North Shore Medical Center. Beth Israel includes: Beth Israel 
Deaconess Medical Center, BID-Milton, BID-Needham, and BID-Plymouth. Lahey includes: Lahey 
Hospital and Medical Center, Northeast, and Winchester. Steward includes: St. Elizabeth’s Medical 
Center, Carney, Good Samaritan Medical Center, Holy Family, Morton, Nashoba Valley, Norwood, 
and Saint Anne’s. Wellforce includes: Tufts Medical Center, Lowell General, and Hallmark. UMass 
Memorial includes: UMass Memorial Medical Center, Clinton, HealthAlliance, and Marlborough. 
Mass. Eye and Ear, Boston Children’s, and South Shore were independent in 2017. The bottom graph 
shows hospital systems with affiliations as of 2019 (with the same 2017 data). Partners now also 
includes: Mass. Eye and Ear. Beth Israel-Lahey includes: all the hospitals under Beth Israel in 2017, 
all the hospitals under Lahey in 2017, Anna Jaques, Mount Auburn, and New England Baptist. All 
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Sources: HPC analysis of Center for Health Information and Analysis All-Payer Claims Database 
v7.0; AHRQ surgery flags
AFFILIATIONS AS OF 2017
AFFILIATIONS AS OF 2019
Both major and minor hospital outpatient surgeries 
are highly concentrated in a few hospital systems, and 
this concentration continues to grow
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An even larger share of minor outpatient surgeries took place 
in the Partners HealthCare and Beth Israel systems (37 percent 
of volume and 41 percent of spending) in 2017.xv These two 
systems performed 39 percent of all hospital-based outpatient 
colonoscopies and 38 percent of breast biopsies in 2017. This 
high and growing concentration of surgeries in several high-
priced AMC-anchored systems is similar to trends found in 
inpatient care (see Chartpack).
It is also important to understand whether this concentration 
is increasing over time. For example, hospital systems often 
note plans to move procedures from AMC hubs to community 
hospitals outside the Boston area, particularly when these 
hospitals are closer to patients’ homes and are lower-cost.xvi 
Although this data only allows observation of changes in 
the concentration of surgeries across hospitals from 2015 to 
2017, there was no evidence of either major or minor surgeries 
shifting away from AMCs and toward community hospitals 
during this time. Between 2015 and 2017, the share of major 
outpatient surgeries taking place at community hospitals fell; 
the share at high public payer community hospitals fell by 
2 percentage points (from 24.8 percent to 22.9 percent) and 
the share at other community hospitals fell by 0.1 percentage 
points from 21.4 down to 21.3 percent. Notably, as described 
above, the share of hysterectomies occurring at AMCs increased 
from 31.6 percent to 37.5 percent from 2015 to 2017. At the 
same time, the combined AMC share of volume of three minor 
diagnostic surgeries examined increased slightly: colonoscopies 
with biopsy (1.4 percent), upper gastrointestinal endoscopies 
with biopsy (1.2 percent), and breast biopsies (2 percent).
xv If this was examined after recent acquisition and merger activity 
(Partners Healthcare with Mass. Eye and Ear and the creation of Beth 
Israel-Lahey), these two systems combined would represent 52 percent 
of volume and 53 percent of spending for minor hospital outpatient 
surgeries.
xvi Several Notices of Material Change fall into this category, including 
the following: https://www.mass.gov/doc/beth-israel-deaconess-med-
ical-center-4/download, https://www.mass.gov/doc/mcn-notices-lhs/
download, and https://www.mass.gov/doc/tufts-medical-center-0/
download.
PAYMENT VARIATION IN MAJOR AND MINOR 
OUTPATIENT SURGERIES
As implied by Exhibit 4.7 and several previous examples, there 
is considerable variation in average payments for hospital 
outpatient surgeries, with payments per surgery varying by 
roughly a factor of two, even among the six highest-volume 
hospitals (see Exhibit 4.8). Exhibit 4.8 shows an example of 
three major surgeries for the six highest-volume hospitals for 
each procedure.
In particular, average payments at Massachusetts General Hos-
pital were 43 percent higher than the median for knee surgery 
and 45 percent higher for cholecystectomy, while the average 
RVUs per procedure were about the same as other hospitals, 
indicating that complexity of surgeries was comparable. The 
average payment for hysterectomy was 77 percent to 78 percent 
above the median hospital in both Partners HealthCare’s AMCs. 
RVUs per procedure at Massachusetts General Hospital (but 
not Brigham and Women’s) were six percent higher than for 
outpatient hysterectomies at other hospitals, indicating that 
they performed slightly more complex procedures. Minor 
outpatient surgeries exhibited a similar pattern (see Exhibit 4.9).
As with major outpatient surgery, although payments vary 
somewhat less overall, Partners Healthcare’s AMCs receive 
payments roughly 40 percent above the median hospital.
The share of hysterectomies occurring  
at AMCs increased from 31.6 percent to  
37.5 percent from 2015 to 2017
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CHOLECYSTECTOMY EXCISION OF KNEE MENISCUS HYSTERECTOMY
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hospitals with at least 10 surgeries. Payments include both hospital and professional fees.
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Exhibit 4�9 Average payment by hospital for three minor outpatient surgeries: upper gastrointestinal endoscopy 
and biopsy, colonoscopy and biopsy, and breast biopsy and other diagnostic procedures, 2017
Exhibit 4�8 Average payment by hospital for three major outpatient surgeries: hysterectomy, knee repair, and 
cholecystectomy, 2017
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SHIFTS FROM LOWER-PRICED TO  
HIGHER-PRICED PROVIDERS
Finally, in addition to volume and price increases for a given 
surgery, hospital outpatient spending can increase if outpatient 
procedures shift from lower-priced hospitals to higher-priced 
hospitals.xvii For most of the major and minor outpatient sur-
geries included in the analysis, the HPC observed such shifts 
from lower-priced hospital outpatient facilities to higher-priced 
ones, leading to increased average payments (see Exhibit 4.10).
In Exhibit 4.10, a positive percentage (to the right) indicates 
that the shift across hospitals from 2015 to 2017 in which 
the procedures were performed increased average payment 
for the procedure. For example, if distribution of outpatient 
surgeries across hospitals stayed the same between 2015 and 
2017, the payment increased for myringotomies, knee car-
tilage excisions, and plastic procedures on the nose would 
have been at least three percent lower than they were. Eight 
of the top eleven major outpatient surgeries experienced such 
a shift (minor surgeries not shown).xviii However, there were 
some outpatient surgeries where there was a shift away from 
highest-cost providers. For example, the average payment 
increase for lumpectomies was 12 percent over this period, but 
would have been 14.8 percent had the volume of procedures 
by hospital stayed the same in 2017 as it was in 2015.
CONCLUSION
A deeper analysis of outpatient surgery as a main component of 
hospital outpatient spending and spending growth has revealed 
a number of factors underlying the spending growth. Among 
major outpatient surgeries, average payments for surgery grew 
10 percent from 2015 to 2017 while volume increased for some 
procedures (sometimes due to shifts from inpatient care) and 
declined for others. Among minor outpatient surgeries, such 
as colonoscopy with biopsy, volume grew while payments 
were relatively unchanged from 2015 to 2017, possibly due 
to competition from non-hospital settings.xix In both cases, 
procedure volume shifted from lower-cost community hospitals 
to higher-cost AMCs, also driving spending growth.
xvii This section considers only shifts within the category of hospital 
outpatient spending, in contrast to Exhibit 4.5, which considered 
shifting from hospital inpatient settings to hospital outpatient settings.
xviii “Other hernia repair,” the 12th major surgery category shown in 
Exhibit 4.4, was not included in Exhibit 4.10 because of the large 
increase in work RVUs from 2015 to 2017. It may be that any shifting 
between hospitals that occurred for this surgery was warranted by 
the complexity of the procedure.
Generally, as clinical practice and population health needs 
lead to less care requiring intensive inpatient settings, the 
Commonwealth would benefit from net savings to employers, 
governments, and consumers. Yet, such savings have not been 
realized for several reasons as discussed in this chapter, namely: 
(1) increases in prices for the same inpatient admissions and 
procedures; (2) changes in coding practices leading to the same 
inpatient care being billed at higher rates; and (3) shifting from 
lower-cost inpatient and hospital outpatient sites of care to 
more expensive outpatient settings. In the recommendations 
section, the HPC discusses provisions stemming from these 
findings that would help Massachusetts residents gain potential 
savings and improve the affordability and value of health care.
xix While some net increases in volume for minor surgeries were observed, 
it is difficult to determine, for the most part, whether this increase 
represents appropriate, high-value care for additional patients or poten-
tially low-value procedures on patients who only benefit marginally.
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Lumpectomy of the  breast
Cholecystectomy
Bunionectomy 
Tonsillectomy adenoidectomy
Inguinal and femoral hernia
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Notes: This graphic is based on a hypothetical counterfactual scenario in which 
the distribution in volume of these procedures across hospitals remained the 
same from 2015 to 2017. The percent change in payment due to shifts across 
facilities was calculated by taking the percent change in actual payments per 
surgery minus the percent increase in hypothetical payments (if volume did 
not shift between hospitals).
Sources: HPC analysis of Center for Health Information and Analysis All-
Payer Claims Database v7.0
Exhibit 4�10 Percent increase in payments due to movement across 
hospital outpatient facilities, 2015 – 2017
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CHAPTER 5:  
POLICY RECOMMENDATIONS
In light of the findings presented in this report, as well as the 
HPC’s research, policy, and program endeavors over the past 
seven years, the HPC has developed policy recommenda-
tions for market participants, policymakers, and government 
agencies. These include  NEW  recommendations for 2019, 
designated in blue, and revised recommendations from previous 
years. For the renewed recommendations, continued action, 
effort, and attention are required by the Commonwealth to 
address the policy issues. Notably, many of these recom-
mendations align with the principles and goals contained in 
recently filed comprehensive legislation by the Baker-Polito 
Administration, as well as recent legislative initiatives. The 
HPC stands ready to support these efforts with data insights 
and independent policy leadership.
Throughout these recommendations, the term 
“The Commonwealth” is intended to be broadly inclusive of 
all relevant stakeholders, both public and private, that influence 
the delivery and payment of health care in Massachusetts and 
whose commitment to action is necessary for advancing the 
recommended policy changes.
In the coming year, the HPC will pursue and support the 
activities outlined below to advance the goal of a more trans-
parent, accountable, and innovative health care system in 
Massachusetts.
2019 POLICY RECOMMENDATIONS
 NEW  1� PRIMARY AND BEHAVIORAL HEALTH CARE� The 
Commonwealth should take action to increase spending in 
primary and behavioral health care. There is considerable 
evidence that health care delivery systems oriented toward 
primary care tend to have lower costs, higher quality, and a 
more equitable distribution of health care resources. Better 
management of behavioral health conditions has also been 
found to lower overall health care spending and improve 
quality of life. Specific areas of focus should include:
a.  Focused investment in primary and behavioral health care: 
Payers and providers should increase spending (both direct 
spending on services and indirect investments such as care 
management infrastructure) devoted to primary care and 
behavioral health, while adhering to the Commonwealth’s 
total health care spending benchmark. Center for Health 
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Information Analysis (CHIA) and the HPC should track and 
report on primary care and behavioral health care spending 
trends annually and hold entities accountable for meeting 
improvement targets if they fall short of benchmark spending.
b.  Improve access to primary and behavioral health care: 
Policymakers, payers, and providers should support 
advancements in technology that improve access to and 
use of primary and behavioral health care, such as telehealth 
services, by creating the infrastructure necessary to deploy 
this intervention across the Commonwealth and approving 
payment for tele-visits and consultations. Lawmakers should 
amend scope of practice laws that are restrictive and not 
evidence-based, including for Advanced Practice Registered 
Nurses (APRNs), and continue to support and strengthen 
the health care workforce with roles designed to meet the 
unique needs of the communities and patient populations 
they serve (e.g., community health workers, patient navi-
gators, peer support specialists, recovery coaches).
 NEW  2� AMBULATORY CARE� The Commonwealth should 
closely scrutinize how care is delivered and paid for in ambu-
latory settings. Given the importance of outpatient care in 
driving spending and utilization trends, the Commonwealth 
should analyze ambulatory care across different sites and 
settings, including urgent care and hospital main campus 
and off-campus sites. Regulators, payers, and other stake-
holders should also examine provider plans for outpatient 
service expansions and consider critically how new projects 
are likely to impact cost, quality, access, and competition in 
the provider market.
 NEW  3� CODING INTENSITY� The Commonwealth should 
take action to mitigate impacts of clinical documentation 
on spending and performance measurement. The HPC has 
found evidence that increases in patient risk scores and acuity 
in recent years are better explained by changes in payer and 
provider documentation and coding practice than by changes 
in actual patient health status. While there are benefits to more 
complete and accurate coding, increased coding intensity also 
impairs accurate performance measurement and has resulted 
in millions in additional spending for Massachusetts residents. 
Specific areas of action should include:
a.  Program update frequency: Public and private payers should 
update the software programs that define and categorize 
inpatient hospital stays, severity levels, and weights more 
frequently to better align payments with actual resource use.
b. Offsets to increases: Public and private payers should 
implement mechanisms to offset the spending impact of cod-
ing-related acuity increases and help to redirect administrative 
efforts away from aggressive coding toward activities with 
greater patient benefit.
c. Alternative risk adjustment and performance measures: 
Public and private payers, policymakers, and third par-
ties should continue to develop alternative risk adjustment 
methods and performance measures that are less sensitive 
to coding-based acuity. Importantly, as discussed in Recom-
mendation #5, given the influence of coding activity on health 
status adjustment, measurement of performance under the 
benchmark should not be triggered exclusively by growth in 
health status adjusted total medical expenses. 
4� PHARMACEUTICAL SPENDING� The Commonwealth should 
take action to reduce drug spending growth. Pharmaceutical 
spending growth in Massachusetts continues to outpace most 
other categories of health care services and exceed the health 
care cost growth benchmark. Massachusetts should build 
on its current initiatives with further innovative approaches. 
Specific areas of focus should include:
 a.  NEW  Enhanced oversight and transparency: Policymakers 
should take action to increase oversight and transparency 
for the full drug distribution chain, including: (1) autho-
rizing the expansion of the HPC’s review to drugs with a 
financial impact to the commercial market in Massachusetts; 
(2) imposing a penalty on manufacturers that increase the 
price of a drug above an inflation-based threshold level; (3) 
increasing state oversight of pharmacy benefit managers’ 
(PBM) pricing practices; and (4) requiring manufacturers 
and PBMs to participate in the HPC’s annual cost trends 
hearing and report data for inclusion in CHIA’s and the 
HPC’s annual reports on health care cost drivers. The phar-
maceutical industry, including manufacturers and PBMs, 
should contribute to the health care industry assessment 
that supports state market oversight activities.
b.  Payer and provider strategies to maximize value and enhance 
access: Payers and providers should pursue a range of strate-
gies to maximize value in drug spending, including: (1) use of 
risk-based contracting with manufacturers and value-based 
benchmarks when negotiating prices; (2) development, in 
collaboration with patient groups, of treatment protocols 
and guidelines for use of high-cost drugs; (3) distribution of 
clinical decision-making tools; (4) monitoring of prescribing 
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patterns to ensure compliance with value-based and evi-
dence-based guidelines; and (5) development of plan designs 
that minimize financial barriers to high-value drugs
 NEW  5� ACCOUNTABILITY UNDER THE COST GROWTH 
BENCHMARK� The Commonwealth should strengthen its abil-
ity to hold health care entities, including hospitals, responsible 
for their spending growth. To improve the annual performance 
improvement plan (PIP) process, policymakers should: (1) 
address current limitations of the data the CHIA is required 
to use in identifying health care entity spending performance 
by expanding the metrics used to identify health care entities 
for review; and (2) strengthen the HPC’s ability to hold health 
plans and providers accountable for spending that impacts the 
health care cost growth benchmark by enhancing financial pen-
alties for above benchmark performance and noncompliance.
 NEW  6� EMPLOYER ENGAGEMENT AND CONSUMER CHOICE� 
The Massachusetts business community should increase its level 
of coordinated engagement to drive improvements or positive 
changes in health care. As major purchasers of health insurance 
and health care services, employers have a powerful voice to 
demand higher value from both payers and providers. Employ-
ers are uniquely positioned to encourage value-based choices 
not only through purchasing decisions, but also by continu-
ous engagement of employees and their families. By working 
collaboratively with payers, providers, and other stakeholders 
through efforts such as the Massachusetts Employer Health 
Coalition, employers can use their influence to drive changes 
in spending and affordability, care delivery, and the promo-
tion of a value-based market. Specific levers include lowering 
premium contributions when employees choose plans favoring 
efficient providers, contracting with payers and providers using 
two-sided risk contracts, and offering group coverage through 
Health Connector for Business if eligible. To further support 
these strategies, policymakers should take action to broaden 
employer access to a wide range of insurance products for 
their employees and to ensure that payers make affordable, 
high-value products available.
7� ADMINISTRATIVE COMPLEXITY� The Commonwealth 
should act to address areas of administrative complexity that 
add cost to the health care system without improving the value 
of care. Administrative complexity is endemic in the U.S. health 
care system. It is one of the principal reasons that U.S. health 
care spending exceeds that of other high-income countries and 
is a source of significant pain – both financial and non-financial 
– to patients and providers alike. The Commonwealth should 
be a national leader by requiring greater standardization of 
common administrative tasks across payers, particularly those 
that affect patients (e.g., prior authorization) and should facili-
tate efforts among government, payers, providers, and patients 
to identify and reduce other drivers of valueless administrative 
complexity.
8� FACILITY FEES� The Commonwealth should limit certain 
facility fees. In many cases, the same services can be provided 
at both hospital outpatient departments and physician offices, 
but rates and patient cost-sharing are often substantially higher 
at hospital outpatient departments due to the addition of hos-
pital “facility fees.” In order to enhance market functioning 
and consumer protections, policymakers should take action 
to require site-neutral payments for common ambulatory ser-
vices (e.g., basic office visits) and limit the cases in which both 
newly licensed and existing sites can bill as hospital outpatient 
departments. Additionally, outpatient sites that charge facility 
fees should be required to conspicuously and clearly disclose 
this fact to patients, prior to delivering care.
9. OUT-OF-NETWORK BILLING. The Commonwealth should 
enhance protections for consumers from out-of-network bills. 
The Commonwealth should protect consumers and improve 
health care market functioning by enacting a comprehensive 
law to address out-of-network billing. Specific provisions 
should include requiring advance patient notification when a 
provider may be out-of-network, protecting consumers from 
out-of-network bills in emergency and “surprise” billing sce-
narios, and setting a reasonable and fair reimbursement rate 
for out-of-network services through a statutory or regula-
tory process. To ensure that such measures do not increase 
total spending, any such process should avoid using provider 
charges or list prices as benchmarks in determining payment.  
10� ALTERNATIVE PAYMENT METHODS� The Commonwealth 
should continue to promote the increased adoption and effec-
tiveness of alternative payment methods (APMs), especially 
in the commercial market where APM expansion has stalled. 
Specific areas of focus should include:
a.  Increase use of APMs for Preferred Provider Organization 
(PPO) populations: Payers should universally use the Mas-
sachusetts consensus guidelines for patient attribution for 
PPO members and support the training and infrastructure 
necessary to manage total cost of care for a PPO population.
b.  Align and improve APM effectiveness: Payers should 
align and improve APM features, including: (1) using the 
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consensus quality measure set developed by the Executive 
Office of Health and Human Services Quality Alignment 
taskforce; (2) providing consistent, timely, actionable data 
for population health management; and (3) for experienced 
providers, shifting to two-sided risk models to maximize the 
impact of the incentives to improve health outcomes and 
value. Payers should move away from historical spending 
as the basis of global budgets and establish stricter targets 
for spending growth for highly paid providers in order to 
lessen unwarranted disparities in global budgets.
c.  Encourage targeted risk: Payers and providers should adopt 
bundled payments for common and costly episodes of care 
such as joint replacement, cardiac procedures, and labor 
and delivery.
11� HEALTH DISPARITIES� The Commonwealth should seek 
to understand and address inequities in the opportunities 
and resources available to enable health and well-being for 
all citizens. Persistent disparities in health outcomes remain 
among low-income communities, people of color, LGBTQ+ 
individuals, and other populations in the Commonwealth, 
despite Massachusetts’ long-standing commitment to increase 
access to care and investments in public health initiatives. To 
address these disparities, specific areas of focus should include:
a.  Health-related social needs (HRSN): Policymakers should 
encourage downstream collaborations between health care 
providers and social service organizations to identify and 
HRSN of patients, including but not limited to housing 
instability, food insecurity, transportation challenges, and 
income instability.
b.  Social determinants of health (SDOH): The Commonwealth 
should promote upstream collaborations among government 
agencies, health care providers, payers, and communi-
ty-based organizations to understand the root causes of 
health inequity in communities – the social determinants 
of health (SDOH) – and leverage their combined expertise, 
resources, and influence to address those inequities through 
strategic investments, policy advocacy and alignment, and 
authentic engagement with community members.
12� INVESTING IN INNOVATION, LEARNING, AND DISSEM-
INATION� The Commonwealth should continue to support 
targeted investments to promote innovation, learning, and 
dissemination of promising care models. Specific opportunities 
for investment include: (1) longitudinal care models to support 
individuals and families experiencing the direct and indirect 
effects of substance use disorder; (2) alternatives to traditional 
hospital-based clinical care (e.g., “hospital at home”); (3) tele-
health as a strategy to increase access to high- need services, 
particularly behavioral health; (4) care models that promote 
coordination and integration of inpatient and ambulatory 
medical and behavioral health, and social services; and (5) 
maternal health, particularly among populations for which 
there are significant disparities in outcomes.
13. LOW VALUE CARE. The Commonwealth should act to 
reduce the provision of health care that does not provide value 
to patients. Payers, providers, and purchasers should collaborate 
on strategies to reduce low value care through measurement, 
reporting, education, and appropriate financial incentives and 
support for incorporating evidence-based guidelines into practice. 
The Commonwealth should encourage information campaigns 
like Choosing Wisely® that disseminate research findings about 
low value care to engage patients in their care and ensure they 
are informed about clinical value before they seek services. 
Consistent with Recommendation #6, employers can also play 
a role in assisting employees and their families in accessing 
information useful in making high-value treatment decisions. 
14� PROVIDER PRICE VARIATION� The Commonwealth should 
take action to reduce unwarranted variation in provider prices. 
Extensive variation in prices paid to health care providers for the 
same medical services and medical drugs due to differences in 
negotiating leverage is a persistent issue in the Commonwealth, 
driving increased health care spending and perpetuating inequi-
ties in the distribution of health care resources across different 
communities. Policymakers should advance specific, data-driven 
interventions to address the pressing issue of persistent provider 
price variation, particularly given new findings indicating that 
savings from shifts from inpatient to outpatient care may be 
lost due to hospital price differentials.
15� AFFORDABILITY� Health care affordability must remain a 
central focus of the Commonwealth’s health care agenda. While 
the Commonwealth successfully met the benchmark for total 
health care spending growth in 2018, health care continues to 
consume an ever greater share of families’ disposable income. 
These growth trends, combined with already high premium 
levels, are making health care increasingly unaffordable for 
many residents and businesses in Massachusetts. The Com-
monwealth should continue to examine and address the factors 
impacting premium and out-of-pocket cost growth and their 
disproportionate impact on lower-to-middle income residents 
and small businesses.
2019 COST TRENDS REPORTHEALTH POLICY COMMISSION - 53 -
C
H
A
P
T
E
R
  5
MASSACHUSETTS TIME TREND U� S� COMPARISON
Previous Most  Recent
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TY 1 Individuals with high out-of-pocket spending relative to income
7%  
(2013 - 2014)
8%  
(2016 - 2017)
10%  
(2016 - 2017)
2 Family premium contribution for low-wage employers $6,976 (2017) $8,196 (2018) $6,059 (2018)
3 Adults who went without care because of cost in the past year 9% (2013) 9% (2017) 14% (2017)
AL
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EN
T M
ET
HO
DS 4 Percentage of Original Medicare beneficiaries covered by APMs 48.1% (2017) 43.6% (2018) 29.2% (2018)
5 Percentage of commercial HMO patients in APMs 54.8% (2017) 54.7% (2018) N/A N/A
6 Percentage of commercial PPO patients in APMs 22.8% (2017) 23.0% (2018) N/A N/A
7 MassHealth managed care member months under APMs 37.8% (2017) 67.7% (2018) N/A N/A
BE
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8 Growth of THCE per capita (performance assessed relative to 3�1% benchmark) 2.8% (2017) 3.1% (2018) 3.5% (2018)
9 Growth in commercial health care spending per capita (performance assessed relative to 3�1% benchmark) 1.4% (2017) 3.0% (2018) 5.3% (2018)
10 Employer-based health insurance premiums, single coverage $7,031 (2017) $7,443 (2018) $6,715 (2018)
11 Growth in employer-based health insurance premiums, single coverage 6.2% (2017) 5.9% (2018) 5.4% (2018)
12 Benchmark premium for second-lowest-cost exchange plan, single coverage $3,000 (2017) $3,792 (2018) N/A* $5,772 (2018)
13 Growth in the benchmark premium for second-lowest-cost exchange plan, single coverage -2.7% (2017) 26.4% (2018) N/A* 34.0% (2018)
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14 Readmission rate (Medicare) 18.2% (2016) 18.3% (2017) 16.7% (2017)
15 Readmission rate (all payer) 15.4% (2017) 15.4% (2018) N/A N/A
16 ED utilization (per 1,000 persons) 357 (2017) 356 (2018) MA = 485  U.S. = 445 (2017)
17 BH-related ED utilization (per 1,000 persons) 28 (2017) 28 (2018) N/A N/A
18 Avoidable ED Utilization 141 (2017) 140 (2018) N/A N/A
19 Percentage of inpatient discharges to institutional PAC 18.5% (2017) 17.8% (2018) MA = 17.9%  U.S. = 15.3% (2016)
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20 Enrollment in tiered network products 18.8% (2017) 20.0% (2018) N/A N/A
21 Enrollment in limited network products 5.1% (2017) 5.3% (2018) N/A N/A
22 Percentage of discharges in top five networks 53.9% (2017) 53.2% (2018) N/A N/A
23 Share of newborns in community hospitals 51.6% (2017) 50.3% (2018) N/A N/A
Better performance
Similar performance
Worse performance
*Due to the elimination of Cost Sharing Reduction payments in 2018, performance in 2018 is not comparable to earlier years.
Exhibit 5�1 Dashboard of HPC system performance metrics
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Exhibit 5�2 Dashboard of HPC improvement targets
METRIC CURRENT HPC TARGET PERFORMANCE
Growth of total health care expenditures per capita 3.1% (2018) 3.1% (2018)
All-payer readmission rate (The rate at which patients 
who have been discharged are admitted again within 30 
days for all payers)
15.4% (2018) 13.0% (2019)
Percentage of commercial HMO patients in APMs 54.7% (2018) 80.0% (2017)
Percentage of commercial PPO patients in APMs 23.0% (2018) 33.0% (2017)
Percentage of inpatient discharges to institutional PAC 17.8% (2018) 17.1% (2020)
Notes: APM = alternative payment method; BH = behavioral health; ED = emergency department; HMO = health mainte-
nance organization; PAC = post-acute care; PPO = preferred provider organization; THCE = total health care expenditures. 
For additional notes and sources, see Technical Appendix.
Better performance
Projected to meet target
Similar performance
Worse performance
Projected to not meet  
target
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